Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Mean serum 25-hydroxyvitamin D3 concentration at 3-year follow-up was higher among children randomised to receive vitamin D versus placebo (104.3 vs 64.7 nmol/L, respectively; mean difference (MD) 39.7 nmol/L, 95% CI 37.6 to 41.9 nmol/L).

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Double-blind reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Influence of vitamin D supplementation on growth, body composition, pubertal development and spirometry in South African schoolchildren: a randomised controlled trial (ViDiKids)

Source: Article title.

We conducted a multicentre phase 3 double-blind individually randomised placebo-controlled trial of weekly oral vitamin D supplementation in 23 government schools in Cape Town, South Africa, as previously described.

Source: Methods.

At 3-year follow-up, substudy participants were additionally invited to undergo repeat spirometry and DXA scanning and to complete a Tanner self-assessment questionnaire for pubertal development.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Influence of vitamin D supplementation on growth, body composition, pubertal development and spirometry in South African schoolchildren: a randomised controlled trial (ViDiKids)

Randomised controlled trial · BMJ Paediatrics Open · 2024

Original publication title

Influence of vitamin D supplementation on growth, body composition, pubertal development and spirometry in South African schoolchildren: a randomised controlled trial (ViDiKids)

Keren Middelkoop; Lisa Micklesfield; Justine Stewart; Neil Walker; David A Jolliffe; Amy E Mendham; Anna K Coussens; James Nuttall; Jonathan Tang; William D Fraser; Waheedullah Momand; Cyrus Cooper; Nicholas C Harvey; Robert J Wilkinson; Linda-Gail Bekker; Adrian R Martineau

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Weekly oral administration of 10 000 IU vitamin D3 boosted vitamin D status but did not influence growth, body composition, pubertal development or spirometric outcomes in South African schoolchildren.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To determine whether weekly oral vitamin D supplementation influences growth, body composition, pubertal development or spirometric outcomes in South African schoolchildren.

Source: Objective

Study methods

What methods does the paper describe?

Trial design, setting and sponsorship

We conducted a multicentre phase 3 double-blind individually randomised placebo-controlled trial of weekly oral vitamin D supplementation in 23 government schools in Cape Town, South Africa, as previously described.18 19 The primary outcome was the acquisition of tuberculosis infection, as evidenced by the conversion of a QuantiFERON-TB Gold Plus (QFT-Plus) assay result from negative at baseline to positive at 3-year follow-up. The current manuscript reports the effects of the intervention on prespecified secondary outcomes relating to growth in all study participants, and body composition, pubertal development and spirometry in a subset of participants who additionally took part in a nested substudy.

The trial was sponsored by Queen Mary University of London.

Participants

Inclusion criteria for the main trial were enrolment in Grades 1 to 4 at a participating school; age 6 to 11 years at screening; and written informed assent/consent to participate in the main trial provided by children and their parent/legal guardian, respectively. Exclusion criteria for the main trial were a history of previous tuberculosis infection, active tuberculosis disease or any chronic illness other than asthma (including known or suspected HIV infection) prior to enrolment; use of any regular medication other than asthma medication; use of vitamin D supplements at a dose of more than 400 IU/day in the month before enrolment; plans to move away from study area within 3 years of enrolment; inability to swallow a placebo soft gel capsule with ease; and clinical evidence of rickets or a positive QFT-Plus assay result at screening.

An additional inclusion criterion for the substudy was enrolment in Grade 4 at a participating school (ie, only children in Grade 4 were eligible for the substudy).

Enrolment

Full details of enrolment procedures are described in Supplementary Methods (online supplemental material). Eligible participants underwent measurement of weight using a Digital Floor Scale (Charder Medical, Taichung City, Taiwan), height using a portable stadiometer (HM200P, Charder Medical) and waist circumference using a measuring tape. Substudy participants also underwent spirometry according to European Respiratory Society and American Thoracic Society standards20 using a portable spirometer (Carefusion, San Diego, California, USA) and measurement of body composition by dual-energy X-ray absorptiometry (DXA) as described below.

Supplementary data

Supplement file at the original source: open the original paper. This file is not included in this text import.

Randomisation and blinding

Full details of randomisation and blinding procedures have been described previously,18 19 and are presented in Supplementary Methods (online supplemental material). Briefly, eligible and assenting children whose parents consented to their participation in the trial were individually randomised to receive a weekly capsule containing vitamin D3 or placebo for 3 years, with a one-to-one allocation ratio and randomisation stratified by the school of attendance. Treatment allocation was concealed from participants, care providers and all trial staff (including senior investigators and those assessing outcomes) until completion of the trial to maintain the double-blind.

Intervention

Study medication comprised a 3-year course of weekly soft gel capsules manufactured by the Tishcon Corporation (Westbury, New York, USA), containing either 0.25 mg (10 000 international units) cholecalciferol (vitamin D3) in olive oil (intervention arm) or olive oil without any vitamin D3 content (placebo arm). A weekly dose of 10 000 IU (equivalent to 1429 IU/day) was selected in preference to a daily dose of 600 IU (the Recommended Daily Allowance for this age group) because we were concerned that the latter dose would be inadequate to maintain serum 25(OH)D concentrations >50 nmol/L,21 and we felt that adherence to a directly-observed weekly dose would be superior to daily self-administration.22 Weekly supplementation has also been shown to be effective in elevating 25(OH)D concentrations into the physiological range in children by other investigators.23 Active and placebo capsules had identical appearance and taste.

Capsules were taken under direct observation of study staff during school term time. Further details of the administration of study medication are provided in Supplementary Methods (online supplemental material).

Follow-up assessments

At 1-year, 2-year and 3-year follow-up, height, weight and waist circumference were measured as at baseline. At 3-year follow-up, substudy participants were additionally invited to undergo repeat spirometry and DXA scanning and to complete a Tanner self-assessment questionnaire for pubertal development.24

Outcomes

The primary outcome of the main trial, reported elsewhere,18 was the QFT-Plus result at the end of the study. The following secondary outcomes were assessed for all participants: height-for-age, BMI-for-age, waist circumference-for-age and waist-to-height ratio (all participants). Additional outcomes assessed in substudy participants only were: whole body fat mass, fat-free soft tissue mass, % predicted forced vital capacity (FVC), % predicted forced expiratory volume in 1 s (FEV1), % predicted FEV1/FVC, mean Tanner scores for pubic hair (men and women), the external genitalia (men only) or breast development (women only), the proportion of participants reaching menarche by the end of the trial (women only) and mean age at menarche (women who reached menarche by the end of the trial only).

DXA

Body composition (whole body fat mass and fat-free soft tissue mass) was assessed using a Hologic Discovery-W DXA scanner at the Sports Science Institute of South Africa, University of Cape Town. All scans were performed by a trained radiographer on one scanner (Hologic, Bedford, Massachusetts, USA) using standard procedures, and analysed using Apex software (V.13.4.1). Quality assurance checks were carried out prior to scanning and generated coefficients of variation <0.5%. DXA outcomes relating to the effects of the trial intervention on bone mineral content have been reported elsewhere.19

Laboratory assessments

Serum concentrations of 25(OH)D3 were measured using liquid chromatography-tandem mass spectrometry as previously described.25 Further details are presented in Supplementary Methods (online supplemental material).

Sample size

The sample size for the main trial was calculated as the number needed to detect a 25% reduction in the proportion of children with a positive QFT-Plus assay result at a 3-year follow-up (primary outcome) with 80% power and 5% type 1 error, assuming a 3.5% annual risk of QFT-Plus conversion, 20% loss to follow-up and a 5% risk of an indeterminate QFT-Plus assay result at the end of the study.18 The sample size for the substudy was calculated as the number needed to detect an inter-arm difference of 0.35 SDs in mean bone mineral content at the whole body less head and lumbar spine with 88% power and 5% type 1 error, assuming 29% loss to follow-up at 3 years.19

Statistical analyses

Full details of statistical analyses are provided in Supplementary Methods (online supplemental material). Briefly, effects of treatment on age-adjusted and sex-adjusted z-scores for anthropometric outcomes were estimated by fitting allocation to vitamin D versus placebo as the sole fixed effect in a mixed effects linear regression model with a random effect for repeated assessments of each individual participant and a random effect of the school of attendance. Effects of treatment on DXA and spirometric outcomes were analysed using multilevel mixed models with adjustment for baseline values and a random effect for school.

Tanner metrics were analysed in a similar fashion, but restricted to the applicable sex and without baseline adjustment. Prespecified subgroup analyses were conducted to determine whether the effect of vitamin D supplementation was modified by sex (male vs female), baseline deseasonalised 25(OH)D3 concentration (<75 vs ≥75 nmol/L)26 and calcium intake (< vs ≥ median value of 466 mg/day).19 These were performed by repeating efficacy analyses with the inclusion of an interaction term between allocation (to vitamin D vs placebo) and each posited effect-modifier with the presentation of the p value associated with this interaction term.

An Independent Data Monitoring Committee reviewed accumulating serious adverse event data at 6-monthly intervals, and recommended continuation of the trial at each review. No interim efficacy analysis was performed.

Patient and public involvement

The Desmond Tutu HIV Centre’s Community Advisory Group was consulted on the design and conduct of the ViDiKids trial.

Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods Source: Methods

WHAT THIS STUDY ADDS

  • This placebo-controlled phase 3 clinical trial, conducted in 1682 black African schoolchildren in Cape Town, South Africa, showed that a 3-year course of weekly vitamin D supplementation was effective in elevating circulating 25-hydroxyvitamin D concentrations.

  • However, this was not associated with any effect on linear growth, body composition, pubertal development or spirometric lung volumes.

Source: WHAT THIS STUDY ADDS

Results: Participants

A total of 2852 children were screened for eligibility from March 2017 to March 2019, of whom 2271 underwent QFT testing: 1682 (74.1%) QFT-negative children were randomly assigned to receive vitamin D3 (829 participants) or placebo (853 participants) as previously described.18 450/1682 (26.8%) participants in the main trial also participated in the substudy, of whom 228 versus 222 participants were allocated to the vitamin D versus placebo arms, respectively (figure 1). Table 1 presents baseline characteristics of children in the main trial and in the substudy, overall and by study arm.

Mean age was higher among participants in the substudy versus all those in the main trial (10.1 vs 8.9 years, respectively), reflecting the fact that participation in the substudy was restricted to children enrolled in Grade 4. Prevalence of obesity and stunting were lower in the substudy versus the main trial (3.8% vs 5.5%, and 6.4% vs 11.1%, respectively). Baseline characteristics were otherwise well balanced for all participants in the main trial vs those who additionally participated in the substudy: 52.4% vs 52.0% were female and mean serum 25(OH)D3 concentrations were 71.2 nmol/L vs 70.0 nmol/L.

Within the main trial and the substudy, baseline characteristics of those randomised to vitamin D versus placebo were also well balanced. The median duration of follow-up was 3.16 years (IQR, 2.83 to 3.38 years) and was not different between the two study arms. For the main trial, mean serum 25(OH)D3 concentrations at 3-year follow-up were higher among children randomised to receive vitamin D versus placebo (104.3 vs 64.7 nmol/L, respectively; mean difference 39.7 nmol/L, 95% CI for difference 37.6 to 41.9 nmol/L).

Figure 1

Participant flow diagram. QFT, QuantiFERON-TB.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 1

Participants’ baseline characteristics by allocation: main study and substudy

Main study
(n=1682)
Substudy
(n=450 subset)
Overall
(n=1682)
Vitamin D arm
(n=829)
Placebo arm (n=853) Overall
(n=450)
Vitamin D arm
(n=228)
Placebo arm (n=222)
Mean age, years (SD)8.9 (1.4)8.9 (1.4)8.8 (1.3)10.1 (0.7)10.2 (0.7)10.0 (0.6)
Female sex, n (%)880 (52.4)437 (52.8)443 (51.9)234 (52.0)116 (50.9)118 (53.2)
Ethnic origin* Xhosa, n (%)1615 (97.9)788 (97.3)827 (98.5)424 (96.4)214 (96.0)210 (96.8)
Other, n (%)35 (2.1)22 (2.7)13 (1.5)16 (3.6)9 (4.0)7 (3.2)
Type of residenceBrick, n (%)867 (51.5)423 (51.0)444 (52.1)230 (51.1)121 (53.1)109 (49.1)
Informal, n(%)815 (48.5)406 (49.0)409 (47.9)220 (48.9)107 (46.9)113 (50.9)
Parental education*,† Primary school, n (%)60 (3.6)34 (4.1)26 (3.1)24 (5.3)16 (7.0)8 (3.6)
Secondary school or higher, n (%)1618 (96.4)792 (95.9)826 (96.9)426 (94.7)212 (93.0)214 (96.4)
Mean monthly household income, 1000 ZAR (SD)1.88 (2.20)1.81 (2.15)1.95 (2.25)1.57 (2.31)1.52 (2.69)1.63 (1.86)
Mean height-for-age z-score (SD)* −0.55 (1.20)−0.56 (1.26)−0.54 (1.15)−0.43 (0.96)−0.43 (0.98)−0.44 (0.95)
Height-for-age z-score category<−2.00 (stunted), n (%)186 (11.1)99 (11.9)87 (10.2)29 (6.4)16 (7.0)13 (5.9)
≥−2.00, n (%)1496 (88.9)730 (88.1)766 (89.8)421 (93.6)212 (93.0)209 (94.1)
Mean BMI-for-age z-score (SD)* 0.33 (1.03)0.31 (1.03)0.34 (1.03)0.20 (0.97)0.19 (0.92)0.21 (1.02)
BMI-for-age z-score category<−2.00 (thin), n (%)26 (1.5)15 (1.8)11 (1.3)7 (1.6)4 (1.8)3 (1.4)
>−2.00 and ≤1.00, n (%)1223 (72.7)602 (72.6)621 (72.8)354 (78.7)178 (78.1)176 (79.3)
>1.00 and ≤2.00 (overweight), n (%)340 (20.2)165 (19.9)175 (20.5)72 (16.0)42 (18.4)30 (13.5)
>2.00 (obese), n (%)93 (5.5)47 (5.7)46 (5.4)17 (3.8)4 (1.8)13 (5.9)
Mean waist circumference-for-age z-score (SD)* −0.13 (0.90)−0.11 (0.90)−0.15 (0.91)−0.20 (0.98)−0.20 (0.98)−0.20 (0.98)
Mean waist-to-height ratio z-score (SD)* 0.03 (0.85)0.05 (0.83)0.00 (0.86)−0.05 (0.86)−0.05 (0.85)−0.04 (0.88)
Mean whole body fat mass, kg (SD)Not reportedNot reportedNot reported3.71 (2.26)3.66 (2.13)3.77 (2.40)
Mean whole body fat-free soft tissue mass, kg (SD)Not reportedNot reportedNot reported9.27 (1.95)9.39 (2.02)9.15 (1.86)
% predicted FEV1 (SD)Not reportedNot reportedNot reported83.2 (15.7)83.8 (15.2)82.7 (16.2)
% predicted FVC (SD)Not reportedNot reportedNot reported94.8 (18.7)94.6 (18.2)95.0 (19.3)
% predicted FEV1/FVC (SD)Not reportedNot reportedNot reported91.4 (16.9)92.2 (16.3)90.5 (17.5)
Calcium intake* <median, n (%)‡ 817 (50.0)383 (47.6)434 (52.3)248 (56.2)119 (53.6)129 (58.9)
≥median, n (%)‡ 817 (50.0)421 (52.4)396 (47.7)193 (43.8)103 (46.4)90 (41.1)
Mean serum 25(OH)D3 concentration, nmol/L (SD)*,§ 71.2 (14.8)71.2 (14.5)71.1 (15.0)70.0 (13.5)70.4 (12.1)69.6 (14.9)
Serum 25(OH)D3 concentration, category*,§ <25 nmol/L, n (%)1 (0.1)0 (0.0)1 (0.1)1 (0.3)0 (0)1 (0.6)
≥25 nmol/L and <50 nmol/L, n (%)74 (5.4)34 (5.1)40 (5.8)20 (5.5)7 (3.7)13 (7.4)
≥50 nmol/L and <75 nmol/L, n (%)787 (57.7)394 (58.8)393 (56.6)214 (59.0)114 (61.0)100 (56.8)
≥75 nmol/L, n (%)502 (36.8)242 (36.1)260 (37.5)128 (35.3)66 (35.3)62 (35.2)

*Missing data (for bone substudy: ethnicity, n=5 vitamin D arm, n=5 placebo arm; for calcium intake, n=6 vitamin D arm, n=3 placebo arm; for serum 25(OH)D3 concentration, n=66 vitamin D arm, n=62 placebo arm; for serum adjusted calcium and total ALP concentration, n=41 vitamin D arm, n=45 placebo arm; for PTH: n=42 vitamin D arm, n=46 placebo arm; for CTX: n=41 vitamin D arm, n=46 placebo arm; for P1NP: n=43 vitamin D arm, n=46 placebo arm; for fracture study: ethnicity, n=19 vitamin D arm, n=13 placebo arm; parental education, n=3 vitamin D arm, n=1 placebo arm; BMI-for-age z-score, n=2 vitamin D arm, n=0 placebo arm; height-for-age z-score, n=2 vitamin D arm, n=0 placebo arm; for calcium intake, n=25 Vitamin D arm, n=23 placebo arm; for serum 25(OH)D3 concentration, n=159 vitamin D arm, n=159 placebo arm.

†Highest level of education of at least one parent.

‡Median calcium intake 466 mg/day.

§Deseasonalised values.

. ALP, alkaline phosphatase; BMC, bone mineral content; BMI, body mass index; CTX, C-terminal cross-linked telopeptide; N, propeptide; 25(OH)D3, 25-hydroxyvitamin D3; P1NP, serum procollagen type I; PTH, parathyroid hormone; ZAR, South African rand.

Source: Participants Source: Participants Source: Participants

Results: Growth outcomes

Among participants in the main trial, allocation to vitamin D versus placebo did not significantly influence mean height-for-age z-scores at annual follow-up, either overall or within subgroups defined by sex, calcium intake or baseline 25(OH)D concentration (table 2: p values for interaction >0.05). Similarly, no statistically significant effect of the intervention was seen on mean BMI-for-age z-scores (table 3), waist circumference-for-age z-scores (online supplemental table S1) or waist-to-height ratio z-scores (online supplemental table S2), either overall or by subgroup (p values for interaction >0.05).

Among substudy participants, allocation to vitamin D versus placebo did not significantly influence fat mass or fat-free soft tissue mass (online supplemental table S3) or % predicted FEV1 or FEV1/FVC (online supplemental table S4), either overall or by subgroup. For the outcome of % predicted FVC, allocation to vitamin D versus placebo did not have a statistically significant effect overall, or within subgroups defined by calcium intake or baseline 25(OH)D concentration; however, the p value for interaction associated with the subgroup analysis by sex (p=0.049) raised the possibility that this factor might modify the effect of vitamin D on % predicted FVC (online supplemental table S4).

Table 2

Mean height-for-age z-scores at annual follow-up by allocation, main study participants: overall and by subgroup

Follow-up time pointVitamin D arm: mean value (SD) (n)Placebo arm: mean value (SD) (n)Adjusted mean difference (95% CI)* P for time point* Overall P * P for interaction*
Overall1 year−0.22 (1.12) (664)−0.15 (1.07) (661)−0.06 (−0.17 to 0.06)0.330.22Not reported
2 years−0.14 (1.05) (613)−0.06 (1.01) (606)−0.04 (−0.16 to 0.07)0.46
3 years−0.26 (1.04) (670)−0.14 (1.05) (691)−0.08 (−0.19 to 0.03)0.17
By sexBoys1 year−0.31 (1.14) (304)−0.27 (1.06) (306)−0.02 (−0.17 to 0.14)0.850.420.94
2 years−0.21 (1.11) (285)−0.19 (0.95) (283)0.04 (−0.13 to 0.20)0.67
3 years−0.34 (1.07) (310)−0.28 (1.00) (326)−0.03 (−0.19 to 0.13)0.69
Girls1 year−0.15 (1.09) (360)−0.04 (1.07) (355)−0.10 (−0.25 to 0.06)0.210.34
2 years−0.08 (0.99) (328)0.05 (1.06) (323)−0.12 (−0.28 to 0.04)0.14
3 years−0.19 (1.02) (360)−0.02 (1.08) (365)−0.13 (−0.28 to 0.03)0.11
By calcium intake† <median1 year−0.16 (1.05) (314)−0.10 (1.02) (331)−0.04 (−0.18 to 0.11)0.640.020.07
2 years−0.17 (0.96) (288)−0.05 (0.96) (310)−0.04 (−0.19 to 0.11)0.64
3 years−0.28 (0.99) (312)−0.15 (0.99) (362)−0.08 (−0.23 to 0.07)0.29
≥median1 year−0.25 (1.16) (327)−0.18 (1.13) (314)−0.05 (−0.21 to 0.12)0.600.72
2 years−0.07 (1.12) (307)−0.06 (1.06) (279)−0.03 (−0.20 to 0.14)0.76
3 years−0.20 (1.09) (337)−0.13 (1.11) (311)−0.06 (−0.22 to 0.11)0.50
By baseline 25(OH)D concentration‡ <75 nmol/L1 year−0.23 (1.13) (349)−0.03 (1.11) (332)−0.17 (−0.33 to −0.01)0.040.530.50
2 years−0.14 (1.11) (325)0.05 (1.06) (323)−0.12 (−0.28 to 0.04)0.15
3 years−0.25 (1.10) (340)−0.06 (1.07) (359)−0.15 (−0.31 to 0.01)0.07
≥75 nmol/L1 year−0.22 (1.15) (187)−0.25 (0.98) (201)0.02 (−0.17 to 0.22)0.820.15
2 years−0.17 (1.00) (171)−0.08 (0.96) (179)−0.07 (−0.26 to 0.13)0.50
3 years−0.30 (1.00) (196)−0.18 (0.99) (206)−0.06 (−0.25 to 0.13)0.53

*Effect estimates and p values from mixed effects linear regression models including a fixed effect for allocation to vitamin D versus placebo, a random effect for repeated assessments of each individual participant and a random effect of school of attendance.

†Median calcium intake 466 mg/day.

‡Deseasonalised values.

.n, number; 25(OH)D, 25-hydroxyvitamin D.;

Table 3

Mean BMI-for-age z-scores at annual follow-up by allocation, main study participants: overall and by subgroup

Vitamin D arm: mean value (SD)(n)Placebo arm: mean value (SD) (n)Adjusted mean difference (95% CI)P for time pointOverall PP for interaction
Overall1 year0.16 (1.03) (664)0.17 (1.02) (661)−0.02 (−0.14 to 0.09)0.680.86Not reported
2 years0.15 (1.41) (613)0.25 (1.21) (606)−0.09 (−0.20 to 0.03)0.14
3 years0.17 (1.07) (669)0.21 (1.17) (691)−0.04 (−0.16 to 0.07)0.45
By sexBoys1 year0.08 (0.99) (304)−0.00 (0.99) (306)0.09 (−0.08 to 0.27)0.300.590.29
2 years0.00 (1.68) (285)−0.04 (1.30) (283)0.04 (−0.14 to 0.22)0.64
3 years−0.02 (1.04) (309)−0.12 (1.20) (326)0.09 (−0.09 to 0.26)0.33
Girls1 year0.23 (1.06) (360)0.32 (1.02) (355)−0.14 (−0.28 to 0.00)0.060.26
2 years0.28 (1.10) (328)0.50 (1.06) (323)−0.21 (−0.36 to −0.06)0.00
3 years0.33 (1.06) (360)0.50 (1.07) (365)−0.17 (−0.32 to −0.03)0.02
By calcium intake† <median1 year0.15 (1.01) (314)0.15 (1.03) (331)−0.01 (−0.17 to 0.14)0.860.160.08
2 years0.18 (1.08) (288)0.21 (1.34) (310)−0.03 (−0.19 to 0.13)0.75
3 years0.21 (1.07) (312)0.20 (1.14) (362)0.01 (−0.14 to 0.17)0.87
≥median1 year0.18 (1.04) (327)0.22 (1.01) (314)−0.04 (−0.21 to 0.13)0.610.27
2 years0.13 (1.67) (307)0.31 (1.07) (279)−0.15 (−0.32 to 0.03)0.10
3 years0.15 (1.07)(336)0.22 (1.23) (311)−0.09 (−0.26 to 0.08)0.31
By baseline 25(OH)D concentration‡ <75 nmol/L1 year0.30 (1.03) (349)0.28 (0.98) (332)0.03 (−0.14 to 0.19)0.760.310.31
2 years0.22 (1.64) (325)0.31 (1.33) (323)−0.07 (−0.24 to 0.10)0.41
3 years0.25 (1.07) (340)0.34 (1.08) (359)−0.09 (−0.25 to 0.08)0.31
≥75 nmol/L1 year0.02 (0.97) (187)0.09 (1.02) (201)−0.06 (−0.25 to 0.13)0.570.58
2 years0.01 (1.05) (171)0.18 (1.00) (179)−0.11 (−0.30 to 0.09)0.28
3 years0.09 (1.00) (196)0.06 (1.17) (206)0.02 (−0.17 to 0.21)0.87

*Effect estimates and p values from mixed effects linear regression models including a fixed effect for allocation to vitamin D versus placebo, a random effect for repeated assessments of each individual participant and a random effect of school of attendance.

†Median calcium intake 466 mg/day.

‡Deseasonalised values.

.n, number; 25(OH)D, 25-hydroxyvitamin D.;

Source: Growth outcomes Source: Growth outcomes Source: Growth outcomes

Results: Developmental outcomes

Among substudy participants, no statistically significant inter-arm differences were seen in mean Tanner scores for pubic hair (men and women), external genitalia (men only), proportion menstruating (women only), mean age at menarche (women only) or breast development (women only), either overall or within subgroups defined by calcium intake or baseline 25(OH)D concentration (table 4).

Table 4

End-study pubertal development indices by allocation, substudy participants: overall and by subgroup

Vitamin D arm: mean value (SD) (n)Placebo arm: mean value (SD) (n)Adjusted mean difference (95% CI)P valueP for interaction
MalesPubic hair, mean Tanner score (SD) (n)Overall3.15 (0.91) (96)2.81 (0.99) (90)0.25 (−0.02 to 0.51)0.07Not reported
Calcium intake† <median3.13 (0.93) (46)2.73 (1.14) (52)0.29 (−0.10 to 0.67)0.140.39
≥median3.15 (0.90) (48)2.92 (0.75) (38)0.16 (−0.19 to 0.52)0.37
Baseline 25(OH)D concentration‡ <75 nmol/L3.11 (0.92) (44)2.88 (0.92) (42)0.07 (−0.28 to 0.41)0.700.39
≥75 nmol/L3.18 (0.94) (34)2.70 (1.18) (30)0.43 (−0.07 to 0.93)0.09
External genitalia, mean Tanner score (SD) (n)Overall3.19 (0.91) (96)2.90 (0.99) (90)0.17 (−0.09 to 0.43)0.19Not reported
Calcium intake† <median3.28 (0.89) (46)2.81 (1.10) (52)0.35 (−0.01 to 0.71)0.060.07
≥median3.10 (0.93) (48)3.03 (0.82) (38)−0.04 (−0.40 to 0.33)0.84
Baseline 25(OH)D concentration‡ <75 nmol/L3.27 (0.82) (44)2.90 (0.91) (42)0.22 (−0.10 to 0.54)0.180.81
≥75 nmol/L3.15 (1.02) (34)2.87 (1.17) (30)0.30 (−0.17 to 0.77)0.21
FemalesPubic hair, mean Tanner score (SD) (n)Overall3.10 (0.98) (105)3.11 (0.98) (99)−0.09 (−0.35 to 0.17)0.50Not reported
Calcium intake† <median3.15 (0.98) (47)3.15 (1.01) (46)0.01 (−0.38 to 0.40)0.960.60
≥median3.11 (0.92) (54)3.10 (0.97) (50)−0.23 (−0.56 to 0.10)0.17
Baseline 25(OH)D concentration‡ <75 nmol/L3.14 (0.90) (59)3.13 (0.88) (55)−0.03 (−0.35 to 0.28)0.830.94
≥75 nmol/L2.96 (1.22) (26)3.04 (1.08) (24)−0.14 (−0.74 to 0.46)0.65
Breast development, mean Tanner score (SD)(n)Overall3.15 (0.87) (105)3.10 (0.91) (99)−0.03 (−0.26 to 0.20)0.80Not reported
Calcium intake† <median3.15 (0.91) (47)3.22 (0.92) (46)−0.06 (−0.41 to 0.29)0.740.93
≥median3.20 (0.81) (54)3.04 (0.90) (50)−0.05 (−0.36 to 0.26)0.76
Baseline 25(OH)D concentration‡ <75 nmol/L3.27 (0.85) (59)3.07 (0.86) (55)0.15 (−0.16 to 0.45)0.340.48
≥75 nmol/L3.08 (0.93) (26)3.08 (0.97) (24)−0.08 (−0.55 to 0.38)0.73
Proportion menstruatingOverall67/105 (63.81)60/99 (60.61)0.95 (0.51 to 1.77)0.86Not reported
Calcium intake† <median28/47 (59.57)26/46 (56.52)1.33 (0.50 to 3.56)0.570.24
≥median38/54 (70.37)34/50 (68.00)0.56 (0.21 to 1.52)0.26
Baseline 25(OH)D concentration‡ <75 nmol/L43/59 (72.88)35/55 (63.64)1.39 (0.59 to 3.28)0.450.59
≥75 nmol/L16/26 (61.54)15/24 (62.50)0.90 (0.26 to 3.15)0.87
Mean age at menarche, years (SD) (n)Overall11.94 (0.93) (66)11.86 (0.66) (58)−0.03 (−0.31 to 0.25)0.84Not reported
Calcium intake† <median11.89 (0.83) (28)11.71 (0.69) (24)0.12 (−0.26 to 0.49)0.540.32
≥median11.97 (1.01) (37)11.97 (0.63) (34)−0.11 (−0.51 to 0.29)0.58
Baseline 25(OH)D concentration‡ <75 nmol/L12.00 (0.88) (42)11.88 (0.69) (34)0.04 (−0.31 to 0.39)0.820.64
≥75 nmol/L11.88 (1.15) (16)11.93 (0.62) (14)−0.14 (−0.73 to 0.44)0.63

*Effect estimates and p values from multilevel mixed models including a random effect for school of attendance.

†Median calcium intake 466 mg/day.

‡Deseasonalised values.

.n, number; 25(OH)D, 25-hydroxyvitamin D.;

Source: Developmental outcomes Source: Developmental outcomes

Results: Adverse events

Incidence of adverse events by the trial arm has been reported elsewhere.18 No serious events arising in the trial were adjudged related to the administration of vitamin D or placebo.

Source: Adverse events

Discussion

We report findings from the first RCT to investigate the effects of vitamin D supplementation on growth and developmental indices in schoolchildren of black African ancestry. Administration of oral vitamin D supplementation at a dose of 10 000 IU per week for 3 years was effective in boosting vitamin D status, but it did not have statistically significant effects on linear growth, BMI, body composition, spirometric lung volumes or self-assessed pubertal development, either overall or in subgroups defined by sex, calcium intake or baseline vitamin D status.

Null findings from the current study contrast with those from observational studies reporting independent associations between vitamin D deficiency and reduced lean mass,8 slower linear growth,7 childhood obesity9 to 11 and precocious puberty.12 However, they are consistent with those of the only other phase 3 RCT to investigate the effects of vitamin D on growth and development in school-age children that we are aware of, which reported no effect of weekly vitamin D supplementation on growth or development among Mongolian schoolchildren aged 6 to 13 years at baseline.17 Contrasting findings from observational studies vs clinical trials may reflect the fact that the former are more susceptible to the effects of confounding or reverse causality.

Although we observed limited evidence (P for interaction 0.049) to support the hypothesis that the effects of vitamin D on FVC might be modified by sex, this finding may have arisen because of type 1 error, given the multiplicity of analyses conducted.

Our study has several strengths. The intervention was sustained (3 years), allowing ample time for any effects of vitamin D supplementation on outcomes of interest to manifest. Moreover, the intervention was effective in elevating serum 25(OH)D concentrations, reflecting adequacy of the dosing regimen employed as well as good adherence resulting from directly observed administration of weekly supplements in schools during term time. Our large sample size and low rates of loss to follow-up maximised the power to detect modest effects of the intervention, particularly for outcomes that were assessed in the main trial population.

Furthermore, we assessed a broad range of anthropometric and developmental outcomes, that included the use of DXA, the gold standard investigation for the assessment of body composition.

Our study also has some limitations. The baseline prevalence of vitamin D deficiency was low, perhaps reflecting plentiful exposure to sunshine in the study setting.25 Dietary factors are less likely to contribute to this phenomenon, as frequency of intake of oily fish and other foods containing vitamin D did not associate with baseline vitamin D status in the study population.25 Our results cannot therefore be generalised to settings where vitamin D deficiency is common. However, we highlight that results from our trial in Mongolia (where the baseline prevalence of vitamin D deficiency was much higher than we observed in the current study) were also null for outcomes of linear growth and body mass index.17 Accordingly, null results from the current trial cannot be explained simply by the relatively high baseline vitamin D status of participants in Cape Town.

A second potential limitation relates to the fact that pubertal status was assessed by participants themselves, rather than by health professionals, whose judgement may be more objective. However, the double-blind placebo-controlled trial design of our study will have distributed any resultant imprecision equally between study arms, ensuring that bias was not introduced. Moreover, pubertal self-assessment has previously been done by adolescent participants in another South African cohort study, and shown to be reliable.27

In conclusion, we report that oral vitamin D supplementation at a dose of 10 000 IU/week for 3 years was effective in elevating serum 25(OH)D concentrations in schoolchildren of black African ancestry living in Cape Town, South Africa. However, this was not associated with any effects on linear growth, body habitus, spirometric outcomes or pubertal development. Taken together with null results from a trial of weekly vitamin D supplementation with similar outcomes conducted in Mongolia,17 our findings do not support the use of vitamin D supplements to influence child growth or development in populations where rickets have been excluded.

Further research could be conducted to re-evaluate growth and developmental outcomes in the future, to determine whether any adverse effects might be associated with withdrawing vitamin D supplementation from individuals randomised to the intervention arm of this study, who may have become habituated to it during their participation in the trial.

Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion

Results

Participants

A total of 2852 children were screened for eligibility from March 2017 to March 2019, of whom 2271 underwent QFT testing: 1682 (74.1%) QFT-negative children were randomly assigned to receive vitamin D3 (829 participants) or placebo (853 participants) as previously described.18 450/1682 (26.8%) participants in the main trial also participated in the substudy, of whom 228 versus 222 participants were allocated to the vitamin D versus placebo arms, respectively (figure 1). Table 1 presents baseline characteristics of children in the main trial and in the substudy, overall and by study arm.

Mean age was higher among participants in the substudy versus all those in the main trial (10.1 vs 8.9 years, respectively), reflecting the fact that participation in the substudy was restricted to children enrolled in Grade 4. Prevalence of obesity and stunting were lower in the substudy versus the main trial (3.8% vs 5.5%, and 6.4% vs 11.1%, respectively). Baseline characteristics were otherwise well balanced for all participants in the main trial vs those who additionally participated in the substudy: 52.4% vs 52.0% were female and mean serum 25(OH)D3 concentrations were 71.2 nmol/L vs 70.0 nmol/L.

Within the main trial and the substudy, baseline characteristics of those randomised to vitamin D versus placebo were also well balanced. The median duration of follow-up was 3.16 years (IQR, 2.83 to 3.38 years) and was not different between the two study arms. For the main trial, mean serum 25(OH)D3 concentrations at 3-year follow-up were higher among children randomised to receive vitamin D versus placebo (104.3 vs 64.7 nmol/L, respectively; mean difference 39.7 nmol/L, 95% CI for difference 37.6 to 41.9 nmol/L).

Figure 1

Participant flow diagram. QFT, QuantiFERON-TB.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 1

Participants’ baseline characteristics by allocation: main study and substudy

Main study
(n=1682)
Substudy
(n=450 subset)
Overall
(n=1682)
Vitamin D arm
(n=829)
Placebo arm (n=853) Overall
(n=450)
Vitamin D arm
(n=228)
Placebo arm (n=222)
Mean age, years (SD)8.9 (1.4)8.9 (1.4)8.8 (1.3)10.1 (0.7)10.2 (0.7)10.0 (0.6)
Female sex, n (%)880 (52.4)437 (52.8)443 (51.9)234 (52.0)116 (50.9)118 (53.2)
Ethnic origin* Xhosa, n (%)1615 (97.9)788 (97.3)827 (98.5)424 (96.4)214 (96.0)210 (96.8)
Other, n (%)35 (2.1)22 (2.7)13 (1.5)16 (3.6)9 (4.0)7 (3.2)
Type of residenceBrick, n (%)867 (51.5)423 (51.0)444 (52.1)230 (51.1)121 (53.1)109 (49.1)
Informal, n(%)815 (48.5)406 (49.0)409 (47.9)220 (48.9)107 (46.9)113 (50.9)
Parental education*,† Primary school, n (%)60 (3.6)34 (4.1)26 (3.1)24 (5.3)16 (7.0)8 (3.6)
Secondary school or higher, n (%)1618 (96.4)792 (95.9)826 (96.9)426 (94.7)212 (93.0)214 (96.4)
Mean monthly household income, 1000 ZAR (SD)1.88 (2.20)1.81 (2.15)1.95 (2.25)1.57 (2.31)1.52 (2.69)1.63 (1.86)
Mean height-for-age z-score (SD)* −0.55 (1.20)−0.56 (1.26)−0.54 (1.15)−0.43 (0.96)−0.43 (0.98)−0.44 (0.95)
Height-for-age z-score category<−2.00 (stunted), n (%)186 (11.1)99 (11.9)87 (10.2)29 (6.4)16 (7.0)13 (5.9)
≥−2.00, n (%)1496 (88.9)730 (88.1)766 (89.8)421 (93.6)212 (93.0)209 (94.1)
Mean BMI-for-age z-score (SD)* 0.33 (1.03)0.31 (1.03)0.34 (1.03)0.20 (0.97)0.19 (0.92)0.21 (1.02)
BMI-for-age z-score category<−2.00 (thin), n (%)26 (1.5)15 (1.8)11 (1.3)7 (1.6)4 (1.8)3 (1.4)
>−2.00 and ≤1.00, n (%)1223 (72.7)602 (72.6)621 (72.8)354 (78.7)178 (78.1)176 (79.3)
>1.00 and ≤2.00 (overweight), n (%)340 (20.2)165 (19.9)175 (20.5)72 (16.0)42 (18.4)30 (13.5)
>2.00 (obese), n (%)93 (5.5)47 (5.7)46 (5.4)17 (3.8)4 (1.8)13 (5.9)
Mean waist circumference-for-age z-score (SD)* −0.13 (0.90)−0.11 (0.90)−0.15 (0.91)−0.20 (0.98)−0.20 (0.98)−0.20 (0.98)
Mean waist-to-height ratio z-score (SD)* 0.03 (0.85)0.05 (0.83)0.00 (0.86)−0.05 (0.86)−0.05 (0.85)−0.04 (0.88)
Mean whole body fat mass, kg (SD)Not reportedNot reportedNot reported3.71 (2.26)3.66 (2.13)3.77 (2.40)
Mean whole body fat-free soft tissue mass, kg (SD)Not reportedNot reportedNot reported9.27 (1.95)9.39 (2.02)9.15 (1.86)
% predicted FEV1 (SD)Not reportedNot reportedNot reported83.2 (15.7)83.8 (15.2)82.7 (16.2)
% predicted FVC (SD)Not reportedNot reportedNot reported94.8 (18.7)94.6 (18.2)95.0 (19.3)
% predicted FEV1/FVC (SD)Not reportedNot reportedNot reported91.4 (16.9)92.2 (16.3)90.5 (17.5)
Calcium intake* <median, n (%)‡ 817 (50.0)383 (47.6)434 (52.3)248 (56.2)119 (53.6)129 (58.9)
≥median, n (%)‡ 817 (50.0)421 (52.4)396 (47.7)193 (43.8)103 (46.4)90 (41.1)
Mean serum 25(OH)D3 concentration, nmol/L (SD)*,§ 71.2 (14.8)71.2 (14.5)71.1 (15.0)70.0 (13.5)70.4 (12.1)69.6 (14.9)
Serum 25(OH)D3 concentration, category*,§ <25 nmol/L, n (%)1 (0.1)0 (0.0)1 (0.1)1 (0.3)0 (0)1 (0.6)
≥25 nmol/L and <50 nmol/L, n (%)74 (5.4)34 (5.1)40 (5.8)20 (5.5)7 (3.7)13 (7.4)
≥50 nmol/L and <75 nmol/L, n (%)787 (57.7)394 (58.8)393 (56.6)214 (59.0)114 (61.0)100 (56.8)
≥75 nmol/L, n (%)502 (36.8)242 (36.1)260 (37.5)128 (35.3)66 (35.3)62 (35.2)

*Missing data (for bone substudy: ethnicity, n=5 vitamin D arm, n=5 placebo arm; for calcium intake, n=6 vitamin D arm, n=3 placebo arm; for serum 25(OH)D3 concentration, n=66 vitamin D arm, n=62 placebo arm; for serum adjusted calcium and total ALP concentration, n=41 vitamin D arm, n=45 placebo arm; for PTH: n=42 vitamin D arm, n=46 placebo arm; for CTX: n=41 vitamin D arm, n=46 placebo arm; for P1NP: n=43 vitamin D arm, n=46 placebo arm; for fracture study: ethnicity, n=19 vitamin D arm, n=13 placebo arm; parental education, n=3 vitamin D arm, n=1 placebo arm; BMI-for-age z-score, n=2 vitamin D arm, n=0 placebo arm; height-for-age z-score, n=2 vitamin D arm, n=0 placebo arm; for calcium intake, n=25 Vitamin D arm, n=23 placebo arm; for serum 25(OH)D3 concentration, n=159 vitamin D arm, n=159 placebo arm.

†Highest level of education of at least one parent.

‡Median calcium intake 466 mg/day.

§Deseasonalised values.

. ALP, alkaline phosphatase; BMC, bone mineral content; BMI, body mass index; CTX, C-terminal cross-linked telopeptide; N, propeptide; 25(OH)D3, 25-hydroxyvitamin D3; P1NP, serum procollagen type I; PTH, parathyroid hormone; ZAR, South African rand.

Growth outcomes

Among participants in the main trial, allocation to vitamin D versus placebo did not significantly influence mean height-for-age z-scores at annual follow-up, either overall or within subgroups defined by sex, calcium intake or baseline 25(OH)D concentration (table 2: p values for interaction >0.05). Similarly, no statistically significant effect of the intervention was seen on mean BMI-for-age z-scores (table 3), waist circumference-for-age z-scores (online supplemental table S1) or waist-to-height ratio z-scores (online supplemental table S2), either overall or by subgroup (p values for interaction >0.05).

Among substudy participants, allocation to vitamin D versus placebo did not significantly influence fat mass or fat-free soft tissue mass (online supplemental table S3) or % predicted FEV1 or FEV1/FVC (online supplemental table S4), either overall or by subgroup. For the outcome of % predicted FVC, allocation to vitamin D versus placebo did not have a statistically significant effect overall, or within subgroups defined by calcium intake or baseline 25(OH)D concentration; however, the p value for interaction associated with the subgroup analysis by sex (p=0.049) raised the possibility that this factor might modify the effect of vitamin D on % predicted FVC (online supplemental table S4).

Table 2

Mean height-for-age z-scores at annual follow-up by allocation, main study participants: overall and by subgroup

Follow-up time pointVitamin D arm: mean value (SD) (n)Placebo arm: mean value (SD) (n)Adjusted mean difference (95% CI)* P for time point* Overall P * P for interaction*
Overall1 year−0.22 (1.12) (664)−0.15 (1.07) (661)−0.06 (−0.17 to 0.06)0.330.22Not reported
2 years−0.14 (1.05) (613)−0.06 (1.01) (606)−0.04 (−0.16 to 0.07)0.46
3 years−0.26 (1.04) (670)−0.14 (1.05) (691)−0.08 (−0.19 to 0.03)0.17
By sexBoys1 year−0.31 (1.14) (304)−0.27 (1.06) (306)−0.02 (−0.17 to 0.14)0.850.420.94
2 years−0.21 (1.11) (285)−0.19 (0.95) (283)0.04 (−0.13 to 0.20)0.67
3 years−0.34 (1.07) (310)−0.28 (1.00) (326)−0.03 (−0.19 to 0.13)0.69
Girls1 year−0.15 (1.09) (360)−0.04 (1.07) (355)−0.10 (−0.25 to 0.06)0.210.34
2 years−0.08 (0.99) (328)0.05 (1.06) (323)−0.12 (−0.28 to 0.04)0.14
3 years−0.19 (1.02) (360)−0.02 (1.08) (365)−0.13 (−0.28 to 0.03)0.11
By calcium intake† <median1 year−0.16 (1.05) (314)−0.10 (1.02) (331)−0.04 (−0.18 to 0.11)0.640.020.07
2 years−0.17 (0.96) (288)−0.05 (0.96) (310)−0.04 (−0.19 to 0.11)0.64
3 years−0.28 (0.99) (312)−0.15 (0.99) (362)−0.08 (−0.23 to 0.07)0.29
≥median1 year−0.25 (1.16) (327)−0.18 (1.13) (314)−0.05 (−0.21 to 0.12)0.600.72
2 years−0.07 (1.12) (307)−0.06 (1.06) (279)−0.03 (−0.20 to 0.14)0.76
3 years−0.20 (1.09) (337)−0.13 (1.11) (311)−0.06 (−0.22 to 0.11)0.50
By baseline 25(OH)D concentration‡ <75 nmol/L1 year−0.23 (1.13) (349)−0.03 (1.11) (332)−0.17 (−0.33 to −0.01)0.040.530.50
2 years−0.14 (1.11) (325)0.05 (1.06) (323)−0.12 (−0.28 to 0.04)0.15
3 years−0.25 (1.10) (340)−0.06 (1.07) (359)−0.15 (−0.31 to 0.01)0.07
≥75 nmol/L1 year−0.22 (1.15) (187)−0.25 (0.98) (201)0.02 (−0.17 to 0.22)0.820.15
2 years−0.17 (1.00) (171)−0.08 (0.96) (179)−0.07 (−0.26 to 0.13)0.50
3 years−0.30 (1.00) (196)−0.18 (0.99) (206)−0.06 (−0.25 to 0.13)0.53

*Effect estimates and p values from mixed effects linear regression models including a fixed effect for allocation to vitamin D versus placebo, a random effect for repeated assessments of each individual participant and a random effect of school of attendance.

†Median calcium intake 466 mg/day.

‡Deseasonalised values.

.n, number; 25(OH)D, 25-hydroxyvitamin D.;

Table 3

Mean BMI-for-age z-scores at annual follow-up by allocation, main study participants: overall and by subgroup

Vitamin D arm: mean value (SD)(n)Placebo arm: mean value (SD) (n)Adjusted mean difference (95% CI)P for time pointOverall PP for interaction
Overall1 year0.16 (1.03) (664)0.17 (1.02) (661)−0.02 (−0.14 to 0.09)0.680.86Not reported
2 years0.15 (1.41) (613)0.25 (1.21) (606)−0.09 (−0.20 to 0.03)0.14
3 years0.17 (1.07) (669)0.21 (1.17) (691)−0.04 (−0.16 to 0.07)0.45
By sexBoys1 year0.08 (0.99) (304)−0.00 (0.99) (306)0.09 (−0.08 to 0.27)0.300.590.29
2 years0.00 (1.68) (285)−0.04 (1.30) (283)0.04 (−0.14 to 0.22)0.64
3 years−0.02 (1.04) (309)−0.12 (1.20) (326)0.09 (−0.09 to 0.26)0.33
Girls1 year0.23 (1.06) (360)0.32 (1.02) (355)−0.14 (−0.28 to 0.00)0.060.26
2 years0.28 (1.10) (328)0.50 (1.06) (323)−0.21 (−0.36 to −0.06)0.00
3 years0.33 (1.06) (360)0.50 (1.07) (365)−0.17 (−0.32 to −0.03)0.02
By calcium intake† <median1 year0.15 (1.01) (314)0.15 (1.03) (331)−0.01 (−0.17 to 0.14)0.860.160.08
2 years0.18 (1.08) (288)0.21 (1.34) (310)−0.03 (−0.19 to 0.13)0.75
3 years0.21 (1.07) (312)0.20 (1.14) (362)0.01 (−0.14 to 0.17)0.87
≥median1 year0.18 (1.04) (327)0.22 (1.01) (314)−0.04 (−0.21 to 0.13)0.610.27
2 years0.13 (1.67) (307)0.31 (1.07) (279)−0.15 (−0.32 to 0.03)0.10
3 years0.15 (1.07)(336)0.22 (1.23) (311)−0.09 (−0.26 to 0.08)0.31
By baseline 25(OH)D concentration‡ <75 nmol/L1 year0.30 (1.03) (349)0.28 (0.98) (332)0.03 (−0.14 to 0.19)0.760.310.31
2 years0.22 (1.64) (325)0.31 (1.33) (323)−0.07 (−0.24 to 0.10)0.41
3 years0.25 (1.07) (340)0.34 (1.08) (359)−0.09 (−0.25 to 0.08)0.31
≥75 nmol/L1 year0.02 (0.97) (187)0.09 (1.02) (201)−0.06 (−0.25 to 0.13)0.570.58
2 years0.01 (1.05) (171)0.18 (1.00) (179)−0.11 (−0.30 to 0.09)0.28
3 years0.09 (1.00) (196)0.06 (1.17) (206)0.02 (−0.17 to 0.21)0.87

*Effect estimates and p values from mixed effects linear regression models including a fixed effect for allocation to vitamin D versus placebo, a random effect for repeated assessments of each individual participant and a random effect of school of attendance.

†Median calcium intake 466 mg/day.

‡Deseasonalised values.

.n, number; 25(OH)D, 25-hydroxyvitamin D.;

Developmental outcomes

Among substudy participants, no statistically significant inter-arm differences were seen in mean Tanner scores for pubic hair (men and women), external genitalia (men only), proportion menstruating (women only), mean age at menarche (women only) or breast development (women only), either overall or within subgroups defined by calcium intake or baseline 25(OH)D concentration (table 4).

Table 4

End-study pubertal development indices by allocation, substudy participants: overall and by subgroup

Vitamin D arm: mean value (SD) (n)Placebo arm: mean value (SD) (n)Adjusted mean difference (95% CI)P valueP for interaction
MalesPubic hair, mean Tanner score (SD) (n)Overall3.15 (0.91) (96)2.81 (0.99) (90)0.25 (−0.02 to 0.51)0.07Not reported
Calcium intake† <median3.13 (0.93) (46)2.73 (1.14) (52)0.29 (−0.10 to 0.67)0.140.39
≥median3.15 (0.90) (48)2.92 (0.75) (38)0.16 (−0.19 to 0.52)0.37
Baseline 25(OH)D concentration‡ <75 nmol/L3.11 (0.92) (44)2.88 (0.92) (42)0.07 (−0.28 to 0.41)0.700.39
≥75 nmol/L3.18 (0.94) (34)2.70 (1.18) (30)0.43 (−0.07 to 0.93)0.09
External genitalia, mean Tanner score (SD) (n)Overall3.19 (0.91) (96)2.90 (0.99) (90)0.17 (−0.09 to 0.43)0.19Not reported
Calcium intake† <median3.28 (0.89) (46)2.81 (1.10) (52)0.35 (−0.01 to 0.71)0.060.07
≥median3.10 (0.93) (48)3.03 (0.82) (38)−0.04 (−0.40 to 0.33)0.84
Baseline 25(OH)D concentration‡ <75 nmol/L3.27 (0.82) (44)2.90 (0.91) (42)0.22 (−0.10 to 0.54)0.180.81
≥75 nmol/L3.15 (1.02) (34)2.87 (1.17) (30)0.30 (−0.17 to 0.77)0.21
FemalesPubic hair, mean Tanner score (SD) (n)Overall3.10 (0.98) (105)3.11 (0.98) (99)−0.09 (−0.35 to 0.17)0.50Not reported
Calcium intake† <median3.15 (0.98) (47)3.15 (1.01) (46)0.01 (−0.38 to 0.40)0.960.60
≥median3.11 (0.92) (54)3.10 (0.97) (50)−0.23 (−0.56 to 0.10)0.17
Baseline 25(OH)D concentration‡ <75 nmol/L3.14 (0.90) (59)3.13 (0.88) (55)−0.03 (−0.35 to 0.28)0.830.94
≥75 nmol/L2.96 (1.22) (26)3.04 (1.08) (24)−0.14 (−0.74 to 0.46)0.65
Breast development, mean Tanner score (SD)(n)Overall3.15 (0.87) (105)3.10 (0.91) (99)−0.03 (−0.26 to 0.20)0.80Not reported
Calcium intake† <median3.15 (0.91) (47)3.22 (0.92) (46)−0.06 (−0.41 to 0.29)0.740.93
≥median3.20 (0.81) (54)3.04 (0.90) (50)−0.05 (−0.36 to 0.26)0.76
Baseline 25(OH)D concentration‡ <75 nmol/L3.27 (0.85) (59)3.07 (0.86) (55)0.15 (−0.16 to 0.45)0.340.48
≥75 nmol/L3.08 (0.93) (26)3.08 (0.97) (24)−0.08 (−0.55 to 0.38)0.73
Proportion menstruatingOverall67/105 (63.81)60/99 (60.61)0.95 (0.51 to 1.77)0.86Not reported
Calcium intake† <median28/47 (59.57)26/46 (56.52)1.33 (0.50 to 3.56)0.570.24
≥median38/54 (70.37)34/50 (68.00)0.56 (0.21 to 1.52)0.26
Baseline 25(OH)D concentration‡ <75 nmol/L43/59 (72.88)35/55 (63.64)1.39 (0.59 to 3.28)0.450.59
≥75 nmol/L16/26 (61.54)15/24 (62.50)0.90 (0.26 to 3.15)0.87
Mean age at menarche, years (SD) (n)Overall11.94 (0.93) (66)11.86 (0.66) (58)−0.03 (−0.31 to 0.25)0.84Not reported
Calcium intake† <median11.89 (0.83) (28)11.71 (0.69) (24)0.12 (−0.26 to 0.49)0.540.32
≥median11.97 (1.01) (37)11.97 (0.63) (34)−0.11 (−0.51 to 0.29)0.58
Baseline 25(OH)D concentration‡ <75 nmol/L12.00 (0.88) (42)11.88 (0.69) (34)0.04 (−0.31 to 0.39)0.820.64
≥75 nmol/L11.88 (1.15) (16)11.93 (0.62) (14)−0.14 (−0.73 to 0.44)0.63

*Effect estimates and p values from multilevel mixed models including a random effect for school of attendance.

†Median calcium intake 466 mg/day.

‡Deseasonalised values.

.n, number; 25(OH)D, 25-hydroxyvitamin D.;

Adverse events

Incidence of adverse events by the trial arm has been reported elsewhere.18 No serious events arising in the trial were adjudged related to the administration of vitamin D or placebo.

Source: Results Source: Results Source: Results Source: Results

Abstract: Conclusions

Weekly oral administration of 10 000 IU vitamin D3 boosted vitamin D status but did not influence growth, body composition, pubertal development or spirometric outcomes in South African schoolchildren.

Source: Conclusions
Authors’ abstract

Objective

To determine whether weekly oral vitamin D supplementation influences growth, body composition, pubertal development or spirometric outcomes in South African schoolchildren.

Design

Phase 3 double-blind randomised placebo-controlled trial.

Setting

Socioeconomically disadvantaged peri-urban district of Cape Town, South Africa.

Participants

1682 children of black African ancestry attending government primary schools and aged 6 to 11 years at baseline.

Interventions

Oral vitamin D3 (10 000 IU/week) versus placebo for 3 years.

Main outcome measures

Height-for-age and body mass index-for-age, measured in all participants; Tanner scores for pubertal development, spirometric lung volumes and body composition, measured in a subset of 450 children who additionally took part in a nested substudy.

Results

Mean serum 25-hydroxyvitamin D3 concentration at 3-year follow-up was higher among children randomised to receive vitamin D versus placebo (104.3 vs 64.7 nmol/L, respectively; mean difference (MD) 39.7 nmol/L, 95% CI 37.6 to 41.9 nmol/L). No statistically significant differences in height-for-age z-score (adjusted MD (aMD) −0.08, 95% CI −0.19 to 0.03) or body mass index-for-age z-score (aMD −0.04, 95% CI −0.16 to 0.07) were seen between vitamin D versus placebo groups at follow-up. Among substudy participants, allocation to vitamin D versus placebo did not influence pubertal development scores, % predicted forced expiratory volume in 1 s (FEV1), % predicted forced vital capacity (FVC), % predicted FEV1/FVC, fat mass or fat-free mass.

Conclusions

Weekly oral administration of 10 000 IU vitamin D3 boosted vitamin D status but did not influence growth, body composition, pubertal development or spirometric outcomes in South African schoolchildren.

Trial registration numbers

ClinicalTrials.gov NCT02880982, South African National Clinical Trials Register DOH-27-0916-5527.

Read the full paper

WHAT IS ALREADY KNOWN ON THIS TOPIC

  • Observational studies have reported independent associations between vitamin D deficiency in childhood and slower linear growth, reduced lean mass, obesity and precocious puberty.

  • A phase 2 clinical trial conducted in Mongolia reported that a 6-month course of vitamin D supplementation increased height gain in 113 vitamin D deficient schoolchildren aged 12 to 15 years; however, these results were not confirmed by a recent phase 3 trial conducted in the same setting.

  • Randomised controlled trials to determine the effects of vitamin D supplementation on growth and development in schoolchildren have not been conducted in other settings.

WHAT THIS STUDY ADDS

  • This placebo-controlled phase 3 clinical trial, conducted in 1682 black African schoolchildren in Cape Town, South Africa, showed that a 3-year course of weekly vitamin D supplementation was effective in elevating circulating 25-hydroxyvitamin D concentrations.

  • However, this was not associated with any effect on linear growth, body composition, pubertal development or spirometric lung volumes.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

  • Our findings do not support the use of vitamin D supplementation as an intervention to influence child growth, body composition, pubertal development or spirometric lung volumes.

Introduction

Middle childhood and early adolescence represent key periods for growth and development that have an important influence on stature and health outcomes in later adolescence and adulthood.1 Stunting in childhood has long been recognised to associate with multiple adverse long-term health outcomes,2 and is particularly common in lower-income countries.3 These settings have also witnessed an emerging epidemic of childhood obesity,4 which has in turn been associated with accelerated pubertal development.5 Interventions to alleviate these public health challenges are urgently needed.

Vitamin D is a fat-soluble micronutrient with pleotropic effects on human health.6 Observational studies have reported that vitamin D deficiency, as evidenced by low circulating concentrations of its major metabolite 25-hydroxyvitamin D (25(OH)D), associates with slower linear growth,7 reduced lean mass,8 childhood obesity9 to 11 and precocious puberty,12 13 potentially reflecting the ability of vitamin D to stimulate production of insulin-like growth factor 114 and regulate adipogenesis.15 A phase 2 randomised controlled trial (RCT) conducted in Mongolia reported that a 6-month course of vitamin D supplementation increased height gain in 113 vitamin D deficient schoolchildren aged 12 to 15 years,16 but these results were not confirmed by a recent phase 3 RCT conducted in the same setting.17 RCTs to determine the effects of vitamin D supplementation on growth and development in schoolchildren have not been conducted in other settings representing children at different risks of malnutrition, stunting and obesity.

An opportunity to conduct such an investigation recently arose as part of the ViDiKids trial, a multicentre phase 3 RCT that investigated the effects of weekly oral administration of 10 000 IU vitamin D3 for 3 years on the primary outcome of tuberculosis infection in a cohort of 1682 schoolchildren aged 6 to 11 years living in a socioeconomically disadvantaged peri-urban district of Cape Town, South Africa.18 Height-for-age z-scores and body mass index (BMI)-for-age z-scores were assessed in all participants (n=1682), and Tanner scores for pubertal development, spirometric lung volumes and body composition were assessed in a subset of 450 children who also took part in a nested substudy.

Methods

Trial design, setting and sponsorship

We conducted a multicentre phase 3 double-blind individually randomised placebo-controlled trial of weekly oral vitamin D supplementation in 23 government schools in Cape Town, South Africa, as previously described.18 19 The primary outcome was the acquisition of tuberculosis infection, as evidenced by the conversion of a QuantiFERON-TB Gold Plus (QFT-Plus) assay result from negative at baseline to positive at 3-year follow-up. The current manuscript reports the effects of the intervention on prespecified secondary outcomes relating to growth in all study participants, and body composition, pubertal development and spirometry in a subset of participants who additionally took part in a nested substudy.

The trial was sponsored by Queen Mary University of London.

Participants

Inclusion criteria for the main trial were enrolment in Grades 1 to 4 at a participating school; age 6 to 11 years at screening; and written informed assent/consent to participate in the main trial provided by children and their parent/legal guardian, respectively. Exclusion criteria for the main trial were a history of previous tuberculosis infection, active tuberculosis disease or any chronic illness other than asthma (including known or suspected HIV infection) prior to enrolment; use of any regular medication other than asthma medication; use of vitamin D supplements at a dose of more than 400 IU/day in the month before enrolment; plans to move away from study area within 3 years of enrolment; inability to swallow a placebo soft gel capsule with ease; and clinical evidence of rickets or a positive QFT-Plus assay result at screening.

An additional inclusion criterion for the substudy was enrolment in Grade 4 at a participating school (ie, only children in Grade 4 were eligible for the substudy).

Enrolment

Full details of enrolment procedures are described in Supplementary Methods (online supplemental material). Eligible participants underwent measurement of weight using a Digital Floor Scale (Charder Medical, Taichung City, Taiwan), height using a portable stadiometer (HM200P, Charder Medical) and waist circumference using a measuring tape. Substudy participants also underwent spirometry according to European Respiratory Society and American Thoracic Society standards20 using a portable spirometer (Carefusion, San Diego, California, USA) and measurement of body composition by dual-energy X-ray absorptiometry (DXA) as described below.

Supplementary data

Supplement file at the original source: open the original paper. This file is not included in this text import.

Randomisation and blinding

Full details of randomisation and blinding procedures have been described previously,18 19 and are presented in Supplementary Methods (online supplemental material). Briefly, eligible and assenting children whose parents consented to their participation in the trial were individually randomised to receive a weekly capsule containing vitamin D3 or placebo for 3 years, with a one-to-one allocation ratio and randomisation stratified by the school of attendance. Treatment allocation was concealed from participants, care providers and all trial staff (including senior investigators and those assessing outcomes) until completion of the trial to maintain the double-blind.

Intervention

Study medication comprised a 3-year course of weekly soft gel capsules manufactured by the Tishcon Corporation (Westbury, New York, USA), containing either 0.25 mg (10 000 international units) cholecalciferol (vitamin D3) in olive oil (intervention arm) or olive oil without any vitamin D3 content (placebo arm). A weekly dose of 10 000 IU (equivalent to 1429 IU/day) was selected in preference to a daily dose of 600 IU (the Recommended Daily Allowance for this age group) because we were concerned that the latter dose would be inadequate to maintain serum 25(OH)D concentrations >50 nmol/L,21 and we felt that adherence to a directly-observed weekly dose would be superior to daily self-administration.22 Weekly supplementation has also been shown to be effective in elevating 25(OH)D concentrations into the physiological range in children by other investigators.23 Active and placebo capsules had identical appearance and taste.

Capsules were taken under direct observation of study staff during school term time. Further details of the administration of study medication are provided in Supplementary Methods (online supplemental material).

Follow-up assessments

At 1-year, 2-year and 3-year follow-up, height, weight and waist circumference were measured as at baseline. At 3-year follow-up, substudy participants were additionally invited to undergo repeat spirometry and DXA scanning and to complete a Tanner self-assessment questionnaire for pubertal development.24

Outcomes

The primary outcome of the main trial, reported elsewhere,18 was the QFT-Plus result at the end of the study. The following secondary outcomes were assessed for all participants: height-for-age, BMI-for-age, waist circumference-for-age and waist-to-height ratio (all participants). Additional outcomes assessed in substudy participants only were: whole body fat mass, fat-free soft tissue mass, % predicted forced vital capacity (FVC), % predicted forced expiratory volume in 1 s (FEV1), % predicted FEV1/FVC, mean Tanner scores for pubic hair (men and women), the external genitalia (men only) or breast development (women only), the proportion of participants reaching menarche by the end of the trial (women only) and mean age at menarche (women who reached menarche by the end of the trial only).

DXA

Body composition (whole body fat mass and fat-free soft tissue mass) was assessed using a Hologic Discovery-W DXA scanner at the Sports Science Institute of South Africa, University of Cape Town. All scans were performed by a trained radiographer on one scanner (Hologic, Bedford, Massachusetts, USA) using standard procedures, and analysed using Apex software (V.13.4.1). Quality assurance checks were carried out prior to scanning and generated coefficients of variation <0.5%. DXA outcomes relating to the effects of the trial intervention on bone mineral content have been reported elsewhere.19

Laboratory assessments

Serum concentrations of 25(OH)D3 were measured using liquid chromatography-tandem mass spectrometry as previously described.25 Further details are presented in Supplementary Methods (online supplemental material).

Sample size

The sample size for the main trial was calculated as the number needed to detect a 25% reduction in the proportion of children with a positive QFT-Plus assay result at a 3-year follow-up (primary outcome) with 80% power and 5% type 1 error, assuming a 3.5% annual risk of QFT-Plus conversion, 20% loss to follow-up and a 5% risk of an indeterminate QFT-Plus assay result at the end of the study.18 The sample size for the substudy was calculated as the number needed to detect an inter-arm difference of 0.35 SDs in mean bone mineral content at the whole body less head and lumbar spine with 88% power and 5% type 1 error, assuming 29% loss to follow-up at 3 years.19

Statistical analyses

Full details of statistical analyses are provided in Supplementary Methods (online supplemental material). Briefly, effects of treatment on age-adjusted and sex-adjusted z-scores for anthropometric outcomes were estimated by fitting allocation to vitamin D versus placebo as the sole fixed effect in a mixed effects linear regression model with a random effect for repeated assessments of each individual participant and a random effect of the school of attendance. Effects of treatment on DXA and spirometric outcomes were analysed using multilevel mixed models with adjustment for baseline values and a random effect for school.

Tanner metrics were analysed in a similar fashion, but restricted to the applicable sex and without baseline adjustment. Prespecified subgroup analyses were conducted to determine whether the effect of vitamin D supplementation was modified by sex (male vs female), baseline deseasonalised 25(OH)D3 concentration (<75 vs ≥75 nmol/L)26 and calcium intake (< vs ≥ median value of 466 mg/day).19 These were performed by repeating efficacy analyses with the inclusion of an interaction term between allocation (to vitamin D vs placebo) and each posited effect-modifier with the presentation of the p value associated with this interaction term.

An Independent Data Monitoring Committee reviewed accumulating serious adverse event data at 6-monthly intervals, and recommended continuation of the trial at each review. No interim efficacy analysis was performed.

Patient and public involvement

The Desmond Tutu HIV Centre’s Community Advisory Group was consulted on the design and conduct of the ViDiKids trial.

Results

Participants

A total of 2852 children were screened for eligibility from March 2017 to March 2019, of whom 2271 underwent QFT testing: 1682 (74.1%) QFT-negative children were randomly assigned to receive vitamin D3 (829 participants) or placebo (853 participants) as previously described.18 450/1682 (26.8%) participants in the main trial also participated in the substudy, of whom 228 versus 222 participants were allocated to the vitamin D versus placebo arms, respectively (figure 1). Table 1 presents baseline characteristics of children in the main trial and in the substudy, overall and by study arm.

Mean age was higher among participants in the substudy versus all those in the main trial (10.1 vs 8.9 years, respectively), reflecting the fact that participation in the substudy was restricted to children enrolled in Grade 4. Prevalence of obesity and stunting were lower in the substudy versus the main trial (3.8% vs 5.5%, and 6.4% vs 11.1%, respectively). Baseline characteristics were otherwise well balanced for all participants in the main trial vs those who additionally participated in the substudy: 52.4% vs 52.0% were female and mean serum 25(OH)D3 concentrations were 71.2 nmol/L vs 70.0 nmol/L.

Within the main trial and the substudy, baseline characteristics of those randomised to vitamin D versus placebo were also well balanced. The median duration of follow-up was 3.16 years (IQR, 2.83 to 3.38 years) and was not different between the two study arms. For the main trial, mean serum 25(OH)D3 concentrations at 3-year follow-up were higher among children randomised to receive vitamin D versus placebo (104.3 vs 64.7 nmol/L, respectively; mean difference 39.7 nmol/L, 95% CI for difference 37.6 to 41.9 nmol/L).

Figure 1

Participant flow diagram. QFT, QuantiFERON-TB.

Figure image at the original source: open the original paper. This file is not included in this text import.
Table 1

Participants’ baseline characteristics by allocation: main study and substudy

Main study
(n=1682)
Substudy
(n=450 subset)
Overall
(n=1682)
Vitamin D arm
(n=829)
Placebo arm (n=853) Overall
(n=450)
Vitamin D arm
(n=228)
Placebo arm (n=222)
Mean age, years (SD)8.9 (1.4)8.9 (1.4)8.8 (1.3)10.1 (0.7)10.2 (0.7)10.0 (0.6)
Female sex, n (%)880 (52.4)437 (52.8)443 (51.9)234 (52.0)116 (50.9)118 (53.2)
Ethnic origin* Xhosa, n (%)1615 (97.9)788 (97.3)827 (98.5)424 (96.4)214 (96.0)210 (96.8)
Other, n (%)35 (2.1)22 (2.7)13 (1.5)16 (3.6)9 (4.0)7 (3.2)
Type of residenceBrick, n (%)867 (51.5)423 (51.0)444 (52.1)230 (51.1)121 (53.1)109 (49.1)
Informal, n(%)815 (48.5)406 (49.0)409 (47.9)220 (48.9)107 (46.9)113 (50.9)
Parental education*,† Primary school, n (%)60 (3.6)34 (4.1)26 (3.1)24 (5.3)16 (7.0)8 (3.6)
Secondary school or higher, n (%)1618 (96.4)792 (95.9)826 (96.9)426 (94.7)212 (93.0)214 (96.4)
Mean monthly household income, 1000 ZAR (SD)1.88 (2.20)1.81 (2.15)1.95 (2.25)1.57 (2.31)1.52 (2.69)1.63 (1.86)
Mean height-for-age z-score (SD)* −0.55 (1.20)−0.56 (1.26)−0.54 (1.15)−0.43 (0.96)−0.43 (0.98)−0.44 (0.95)
Height-for-age z-score category<−2.00 (stunted), n (%)186 (11.1)99 (11.9)87 (10.2)29 (6.4)16 (7.0)13 (5.9)
≥−2.00, n (%)1496 (88.9)730 (88.1)766 (89.8)421 (93.6)212 (93.0)209 (94.1)
Mean BMI-for-age z-score (SD)* 0.33 (1.03)0.31 (1.03)0.34 (1.03)0.20 (0.97)0.19 (0.92)0.21 (1.02)
BMI-for-age z-score category<−2.00 (thin), n (%)26 (1.5)15 (1.8)11 (1.3)7 (1.6)4 (1.8)3 (1.4)
>−2.00 and ≤1.00, n (%)1223 (72.7)602 (72.6)621 (72.8)354 (78.7)178 (78.1)176 (79.3)
>1.00 and ≤2.00 (overweight), n (%)340 (20.2)165 (19.9)175 (20.5)72 (16.0)42 (18.4)30 (13.5)
>2.00 (obese), n (%)93 (5.5)47 (5.7)46 (5.4)17 (3.8)4 (1.8)13 (5.9)
Mean waist circumference-for-age z-score (SD)* −0.13 (0.90)−0.11 (0.90)−0.15 (0.91)−0.20 (0.98)−0.20 (0.98)−0.20 (0.98)
Mean waist-to-height ratio z-score (SD)* 0.03 (0.85)0.05 (0.83)0.00 (0.86)−0.05 (0.86)−0.05 (0.85)−0.04 (0.88)
Mean whole body fat mass, kg (SD)Not reportedNot reportedNot reported3.71 (2.26)3.66 (2.13)3.77 (2.40)
Mean whole body fat-free soft tissue mass, kg (SD)Not reportedNot reportedNot reported9.27 (1.95)9.39 (2.02)9.15 (1.86)
% predicted FEV1 (SD)Not reportedNot reportedNot reported83.2 (15.7)83.8 (15.2)82.7 (16.2)
% predicted FVC (SD)Not reportedNot reportedNot reported94.8 (18.7)94.6 (18.2)95.0 (19.3)
% predicted FEV1/FVC (SD)Not reportedNot reportedNot reported91.4 (16.9)92.2 (16.3)90.5 (17.5)
Calcium intake* <median, n (%)‡ 817 (50.0)383 (47.6)434 (52.3)248 (56.2)119 (53.6)129 (58.9)
≥median, n (%)‡ 817 (50.0)421 (52.4)396 (47.7)193 (43.8)103 (46.4)90 (41.1)
Mean serum 25(OH)D3 concentration, nmol/L (SD)*,§ 71.2 (14.8)71.2 (14.5)71.1 (15.0)70.0 (13.5)70.4 (12.1)69.6 (14.9)
Serum 25(OH)D3 concentration, category*,§ <25 nmol/L, n (%)1 (0.1)0 (0.0)1 (0.1)1 (0.3)0 (0)1 (0.6)
≥25 nmol/L and <50 nmol/L, n (%)74 (5.4)34 (5.1)40 (5.8)20 (5.5)7 (3.7)13 (7.4)
≥50 nmol/L and <75 nmol/L, n (%)787 (57.7)394 (58.8)393 (56.6)214 (59.0)114 (61.0)100 (56.8)
≥75 nmol/L, n (%)502 (36.8)242 (36.1)260 (37.5)128 (35.3)66 (35.3)62 (35.2)

*Missing data (for bone substudy: ethnicity, n=5 vitamin D arm, n=5 placebo arm; for calcium intake, n=6 vitamin D arm, n=3 placebo arm; for serum 25(OH)D3 concentration, n=66 vitamin D arm, n=62 placebo arm; for serum adjusted calcium and total ALP concentration, n=41 vitamin D arm, n=45 placebo arm; for PTH: n=42 vitamin D arm, n=46 placebo arm; for CTX: n=41 vitamin D arm, n=46 placebo arm; for P1NP: n=43 vitamin D arm, n=46 placebo arm; for fracture study: ethnicity, n=19 vitamin D arm, n=13 placebo arm; parental education, n=3 vitamin D arm, n=1 placebo arm; BMI-for-age z-score, n=2 vitamin D arm, n=0 placebo arm; height-for-age z-score, n=2 vitamin D arm, n=0 placebo arm; for calcium intake, n=25 Vitamin D arm, n=23 placebo arm; for serum 25(OH)D3 concentration, n=159 vitamin D arm, n=159 placebo arm.

†Highest level of education of at least one parent.

‡Median calcium intake 466 mg/day.

§Deseasonalised values.

. ALP, alkaline phosphatase; BMC, bone mineral content; BMI, body mass index; CTX, C-terminal cross-linked telopeptide; N, propeptide; 25(OH)D3, 25-hydroxyvitamin D3; P1NP, serum procollagen type I; PTH, parathyroid hormone; ZAR, South African rand.

Growth outcomes

Among participants in the main trial, allocation to vitamin D versus placebo did not significantly influence mean height-for-age z-scores at annual follow-up, either overall or within subgroups defined by sex, calcium intake or baseline 25(OH)D concentration (table 2: p values for interaction >0.05). Similarly, no statistically significant effect of the intervention was seen on mean BMI-for-age z-scores (table 3), waist circumference-for-age z-scores (online supplemental table S1) or waist-to-height ratio z-scores (online supplemental table S2), either overall or by subgroup (p values for interaction >0.05).

Among substudy participants, allocation to vitamin D versus placebo did not significantly influence fat mass or fat-free soft tissue mass (online supplemental table S3) or % predicted FEV1 or FEV1/FVC (online supplemental table S4), either overall or by subgroup. For the outcome of % predicted FVC, allocation to vitamin D versus placebo did not have a statistically significant effect overall, or within subgroups defined by calcium intake or baseline 25(OH)D concentration; however, the p value for interaction associated with the subgroup analysis by sex (p=0.049) raised the possibility that this factor might modify the effect of vitamin D on % predicted FVC (online supplemental table S4).

Table 2

Mean height-for-age z-scores at annual follow-up by allocation, main study participants: overall and by subgroup

Follow-up time pointVitamin D arm: mean value (SD) (n)Placebo arm: mean value (SD) (n)Adjusted mean difference (95% CI)* P for time point* Overall P * P for interaction*
Overall1 year−0.22 (1.12) (664)−0.15 (1.07) (661)−0.06 (−0.17 to 0.06)0.330.22Not reported
2 years−0.14 (1.05) (613)−0.06 (1.01) (606)−0.04 (−0.16 to 0.07)0.46
3 years−0.26 (1.04) (670)−0.14 (1.05) (691)−0.08 (−0.19 to 0.03)0.17
By sexBoys1 year−0.31 (1.14) (304)−0.27 (1.06) (306)−0.02 (−0.17 to 0.14)0.850.420.94
2 years−0.21 (1.11) (285)−0.19 (0.95) (283)0.04 (−0.13 to 0.20)0.67
3 years−0.34 (1.07) (310)−0.28 (1.00) (326)−0.03 (−0.19 to 0.13)0.69
Girls1 year−0.15 (1.09) (360)−0.04 (1.07) (355)−0.10 (−0.25 to 0.06)0.210.34
2 years−0.08 (0.99) (328)0.05 (1.06) (323)−0.12 (−0.28 to 0.04)0.14
3 years−0.19 (1.02) (360)−0.02 (1.08) (365)−0.13 (−0.28 to 0.03)0.11
By calcium intake† <median1 year−0.16 (1.05) (314)−0.10 (1.02) (331)−0.04 (−0.18 to 0.11)0.640.020.07
2 years−0.17 (0.96) (288)−0.05 (0.96) (310)−0.04 (−0.19 to 0.11)0.64
3 years−0.28 (0.99) (312)−0.15 (0.99) (362)−0.08 (−0.23 to 0.07)0.29
≥median1 year−0.25 (1.16) (327)−0.18 (1.13) (314)−0.05 (−0.21 to 0.12)0.600.72
2 years−0.07 (1.12) (307)−0.06 (1.06) (279)−0.03 (−0.20 to 0.14)0.76
3 years−0.20 (1.09) (337)−0.13 (1.11) (311)−0.06 (−0.22 to 0.11)0.50
By baseline 25(OH)D concentration‡ <75 nmol/L1 year−0.23 (1.13) (349)−0.03 (1.11) (332)−0.17 (−0.33 to −0.01)0.040.530.50
2 years−0.14 (1.11) (325)0.05 (1.06) (323)−0.12 (−0.28 to 0.04)0.15
3 years−0.25 (1.10) (340)−0.06 (1.07) (359)−0.15 (−0.31 to 0.01)0.07
≥75 nmol/L1 year−0.22 (1.15) (187)−0.25 (0.98) (201)0.02 (−0.17 to 0.22)0.820.15
2 years−0.17 (1.00) (171)−0.08 (0.96) (179)−0.07 (−0.26 to 0.13)0.50
3 years−0.30 (1.00) (196)−0.18 (0.99) (206)−0.06 (−0.25 to 0.13)0.53

*Effect estimates and p values from mixed effects linear regression models including a fixed effect for allocation to vitamin D versus placebo, a random effect for repeated assessments of each individual participant and a random effect of school of attendance.

†Median calcium intake 466 mg/day.

‡Deseasonalised values.

.n, number; 25(OH)D, 25-hydroxyvitamin D.;

Table 3

Mean BMI-for-age z-scores at annual follow-up by allocation, main study participants: overall and by subgroup

Vitamin D arm: mean value (SD)(n)Placebo arm: mean value (SD) (n)Adjusted mean difference (95% CI)P for time pointOverall PP for interaction
Overall1 year0.16 (1.03) (664)0.17 (1.02) (661)−0.02 (−0.14 to 0.09)0.680.86Not reported
2 years0.15 (1.41) (613)0.25 (1.21) (606)−0.09 (−0.20 to 0.03)0.14
3 years0.17 (1.07) (669)0.21 (1.17) (691)−0.04 (−0.16 to 0.07)0.45
By sexBoys1 year0.08 (0.99) (304)−0.00 (0.99) (306)0.09 (−0.08 to 0.27)0.300.590.29
2 years0.00 (1.68) (285)−0.04 (1.30) (283)0.04 (−0.14 to 0.22)0.64
3 years−0.02 (1.04) (309)−0.12 (1.20) (326)0.09 (−0.09 to 0.26)0.33
Girls1 year0.23 (1.06) (360)0.32 (1.02) (355)−0.14 (−0.28 to 0.00)0.060.26
2 years0.28 (1.10) (328)0.50 (1.06) (323)−0.21 (−0.36 to −0.06)0.00
3 years0.33 (1.06) (360)0.50 (1.07) (365)−0.17 (−0.32 to −0.03)0.02
By calcium intake† <median1 year0.15 (1.01) (314)0.15 (1.03) (331)−0.01 (−0.17 to 0.14)0.860.160.08
2 years0.18 (1.08) (288)0.21 (1.34) (310)−0.03 (−0.19 to 0.13)0.75
3 years0.21 (1.07) (312)0.20 (1.14) (362)0.01 (−0.14 to 0.17)0.87
≥median1 year0.18 (1.04) (327)0.22 (1.01) (314)−0.04 (−0.21 to 0.13)0.610.27
2 years0.13 (1.67) (307)0.31 (1.07) (279)−0.15 (−0.32 to 0.03)0.10
3 years0.15 (1.07)(336)0.22 (1.23) (311)−0.09 (−0.26 to 0.08)0.31
By baseline 25(OH)D concentration‡ <75 nmol/L1 year0.30 (1.03) (349)0.28 (0.98) (332)0.03 (−0.14 to 0.19)0.760.310.31
2 years0.22 (1.64) (325)0.31 (1.33) (323)−0.07 (−0.24 to 0.10)0.41
3 years0.25 (1.07) (340)0.34 (1.08) (359)−0.09 (−0.25 to 0.08)0.31
≥75 nmol/L1 year0.02 (0.97) (187)0.09 (1.02) (201)−0.06 (−0.25 to 0.13)0.570.58
2 years0.01 (1.05) (171)0.18 (1.00) (179)−0.11 (−0.30 to 0.09)0.28
3 years0.09 (1.00) (196)0.06 (1.17) (206)0.02 (−0.17 to 0.21)0.87

*Effect estimates and p values from mixed effects linear regression models including a fixed effect for allocation to vitamin D versus placebo, a random effect for repeated assessments of each individual participant and a random effect of school of attendance.

†Median calcium intake 466 mg/day.

‡Deseasonalised values.

.n, number; 25(OH)D, 25-hydroxyvitamin D.;

Developmental outcomes

Among substudy participants, no statistically significant inter-arm differences were seen in mean Tanner scores for pubic hair (men and women), external genitalia (men only), proportion menstruating (women only), mean age at menarche (women only) or breast development (women only), either overall or within subgroups defined by calcium intake or baseline 25(OH)D concentration (table 4).

Table 4

End-study pubertal development indices by allocation, substudy participants: overall and by subgroup

Vitamin D arm: mean value (SD) (n)Placebo arm: mean value (SD) (n)Adjusted mean difference (95% CI)P valueP for interaction
MalesPubic hair, mean Tanner score (SD) (n)Overall3.15 (0.91) (96)2.81 (0.99) (90)0.25 (−0.02 to 0.51)0.07Not reported
Calcium intake† <median3.13 (0.93) (46)2.73 (1.14) (52)0.29 (−0.10 to 0.67)0.140.39
≥median3.15 (0.90) (48)2.92 (0.75) (38)0.16 (−0.19 to 0.52)0.37
Baseline 25(OH)D concentration‡ <75 nmol/L3.11 (0.92) (44)2.88 (0.92) (42)0.07 (−0.28 to 0.41)0.700.39
≥75 nmol/L3.18 (0.94) (34)2.70 (1.18) (30)0.43 (−0.07 to 0.93)0.09
External genitalia, mean Tanner score (SD) (n)Overall3.19 (0.91) (96)2.90 (0.99) (90)0.17 (−0.09 to 0.43)0.19Not reported
Calcium intake† <median3.28 (0.89) (46)2.81 (1.10) (52)0.35 (−0.01 to 0.71)0.060.07
≥median3.10 (0.93) (48)3.03 (0.82) (38)−0.04 (−0.40 to 0.33)0.84
Baseline 25(OH)D concentration‡ <75 nmol/L3.27 (0.82) (44)2.90 (0.91) (42)0.22 (−0.10 to 0.54)0.180.81
≥75 nmol/L3.15 (1.02) (34)2.87 (1.17) (30)0.30 (−0.17 to 0.77)0.21
FemalesPubic hair, mean Tanner score (SD) (n)Overall3.10 (0.98) (105)3.11 (0.98) (99)−0.09 (−0.35 to 0.17)0.50Not reported
Calcium intake† <median3.15 (0.98) (47)3.15 (1.01) (46)0.01 (−0.38 to 0.40)0.960.60
≥median3.11 (0.92) (54)3.10 (0.97) (50)−0.23 (−0.56 to 0.10)0.17
Baseline 25(OH)D concentration‡ <75 nmol/L3.14 (0.90) (59)3.13 (0.88) (55)−0.03 (−0.35 to 0.28)0.830.94
≥75 nmol/L2.96 (1.22) (26)3.04 (1.08) (24)−0.14 (−0.74 to 0.46)0.65
Breast development, mean Tanner score (SD)(n)Overall3.15 (0.87) (105)3.10 (0.91) (99)−0.03 (−0.26 to 0.20)0.80Not reported
Calcium intake† <median3.15 (0.91) (47)3.22 (0.92) (46)−0.06 (−0.41 to 0.29)0.740.93
≥median3.20 (0.81) (54)3.04 (0.90) (50)−0.05 (−0.36 to 0.26)0.76
Baseline 25(OH)D concentration‡ <75 nmol/L3.27 (0.85) (59)3.07 (0.86) (55)0.15 (−0.16 to 0.45)0.340.48
≥75 nmol/L3.08 (0.93) (26)3.08 (0.97) (24)−0.08 (−0.55 to 0.38)0.73
Proportion menstruatingOverall67/105 (63.81)60/99 (60.61)0.95 (0.51 to 1.77)0.86Not reported
Calcium intake† <median28/47 (59.57)26/46 (56.52)1.33 (0.50 to 3.56)0.570.24
≥median38/54 (70.37)34/50 (68.00)0.56 (0.21 to 1.52)0.26
Baseline 25(OH)D concentration‡ <75 nmol/L43/59 (72.88)35/55 (63.64)1.39 (0.59 to 3.28)0.450.59
≥75 nmol/L16/26 (61.54)15/24 (62.50)0.90 (0.26 to 3.15)0.87
Mean age at menarche, years (SD) (n)Overall11.94 (0.93) (66)11.86 (0.66) (58)−0.03 (−0.31 to 0.25)0.84Not reported
Calcium intake† <median11.89 (0.83) (28)11.71 (0.69) (24)0.12 (−0.26 to 0.49)0.540.32
≥median11.97 (1.01) (37)11.97 (0.63) (34)−0.11 (−0.51 to 0.29)0.58
Baseline 25(OH)D concentration‡ <75 nmol/L12.00 (0.88) (42)11.88 (0.69) (34)0.04 (−0.31 to 0.39)0.820.64
≥75 nmol/L11.88 (1.15) (16)11.93 (0.62) (14)−0.14 (−0.73 to 0.44)0.63

*Effect estimates and p values from multilevel mixed models including a random effect for school of attendance.

†Median calcium intake 466 mg/day.

‡Deseasonalised values.

.n, number; 25(OH)D, 25-hydroxyvitamin D.;

Adverse events

Incidence of adverse events by the trial arm has been reported elsewhere.18 No serious events arising in the trial were adjudged related to the administration of vitamin D or placebo.

Discussion

We report findings from the first RCT to investigate the effects of vitamin D supplementation on growth and developmental indices in schoolchildren of black African ancestry. Administration of oral vitamin D supplementation at a dose of 10 000 IU per week for 3 years was effective in boosting vitamin D status, but it did not have statistically significant effects on linear growth, BMI, body composition, spirometric lung volumes or self-assessed pubertal development, either overall or in subgroups defined by sex, calcium intake or baseline vitamin D status.

Null findings from the current study contrast with those from observational studies reporting independent associations between vitamin D deficiency and reduced lean mass,8 slower linear growth,7 childhood obesity9 to 11 and precocious puberty.12 However, they are consistent with those of the only other phase 3 RCT to investigate the effects of vitamin D on growth and development in school-age children that we are aware of, which reported no effect of weekly vitamin D supplementation on growth or development among Mongolian schoolchildren aged 6 to 13 years at baseline.17 Contrasting findings from observational studies vs clinical trials may reflect the fact that the former are more susceptible to the effects of confounding or reverse causality.

Although we observed limited evidence (P for interaction 0.049) to support the hypothesis that the effects of vitamin D on FVC might be modified by sex, this finding may have arisen because of type 1 error, given the multiplicity of analyses conducted.

Our study has several strengths. The intervention was sustained (3 years), allowing ample time for any effects of vitamin D supplementation on outcomes of interest to manifest. Moreover, the intervention was effective in elevating serum 25(OH)D concentrations, reflecting adequacy of the dosing regimen employed as well as good adherence resulting from directly observed administration of weekly supplements in schools during term time. Our large sample size and low rates of loss to follow-up maximised the power to detect modest effects of the intervention, particularly for outcomes that were assessed in the main trial population.

Furthermore, we assessed a broad range of anthropometric and developmental outcomes, that included the use of DXA, the gold standard investigation for the assessment of body composition.

Our study also has some limitations. The baseline prevalence of vitamin D deficiency was low, perhaps reflecting plentiful exposure to sunshine in the study setting.25 Dietary factors are less likely to contribute to this phenomenon, as frequency of intake of oily fish and other foods containing vitamin D did not associate with baseline vitamin D status in the study population.25 Our results cannot therefore be generalised to settings where vitamin D deficiency is common. However, we highlight that results from our trial in Mongolia (where the baseline prevalence of vitamin D deficiency was much higher than we observed in the current study) were also null for outcomes of linear growth and body mass index.17 Accordingly, null results from the current trial cannot be explained simply by the relatively high baseline vitamin D status of participants in Cape Town.

A second potential limitation relates to the fact that pubertal status was assessed by participants themselves, rather than by health professionals, whose judgement may be more objective. However, the double-blind placebo-controlled trial design of our study will have distributed any resultant imprecision equally between study arms, ensuring that bias was not introduced. Moreover, pubertal self-assessment has previously been done by adolescent participants in another South African cohort study, and shown to be reliable.27

In conclusion, we report that oral vitamin D supplementation at a dose of 10 000 IU/week for 3 years was effective in elevating serum 25(OH)D concentrations in schoolchildren of black African ancestry living in Cape Town, South Africa. However, this was not associated with any effects on linear growth, body habitus, spirometric outcomes or pubertal development. Taken together with null results from a trial of weekly vitamin D supplementation with similar outcomes conducted in Mongolia,17 our findings do not support the use of vitamin D supplements to influence child growth or development in populations where rickets have been excluded.

Further research could be conducted to re-evaluate growth and developmental outcomes in the future, to determine whether any adverse effects might be associated with withdrawing vitamin D supplementation from individuals randomised to the intervention arm of this study, who may have become habituated to it during their participation in the trial.

Supplementary Material

Reviewer comments

Supplement file at the original source: open the original paper. This file is not included in this text import.

Author’s manuscript

Supplement file at the original source: open the original paper. This file is not included in this text import.

We thank all the children who participated in the trial, and their parents/guardians; Professor Richard L Hooper for advice on statistical analysis; members of the Independent Data Monitoring Committee (Professor Guy Thwaites, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam (Chair); Professor John Pettifor, University of the Witwatersrand, Johannesburg, South Africa; and Professor Sarah Walker, MRC Clinical Trials Unit, London, UK); and members of the Trial Steering Committee (Professor Beate Kampmann, London School of Hygiene and Tropical Medicine, London, UK (Chair); Professor Ashraf Coovadia, University of the Witwatersrand, Johannesburg, South Africa; Dr Karen Jennings, City Health, Cape Town, South Africa; Dr Robin Dyers, Department of Health, Western Cape Government, Cape Town, South Africa; and Dr Guy de Bruyn, Sanofi Pasteur, Swiftwater, Pennsylvania, USA).

For the purposes of open access the author has applied a CC-BY public copyright to any author-accepted manuscript arising from this submission.

KM and LM contributed equally.

Contributors: ARM conceived the study. KM, LM, AKC, JN, CC, NCH, RLH, RJW, L-GB and ARM contributed to study design and protocol development. KM led on trial implementation, with support from JS, DAJ, JN, L-GB and ARM. LM and AEM oversaw the performance of DXA scans. JT and WDF performed and supervised the conduct of biochemical assays. NW and AM drafted the statistical analysis plan. DAJ, KM, JS, NW and WM managed data. NW accessed, verified and analysed the data underlying the study.

ARM and DAJ wrote the first draft of the trial report. All authors made substantive comments thereon and approved the final version for submission. ARM is guarantor for this report.

Funding: This research was funded by the UK Medical Research Council (refs MR/R023050/1 and MR/M026639/1, both awarded to AM). RJW is supported by The Francis Crick Institute which receives funding from Wellcome (CC2112), Cancer Research UK (CC2112) and UK Research and Innovation (Medical Research Council CC2112). He also receives support from Wellcome (203135) and in part by the NIHR Biomedical Research Centre of Imperial College NHS Trust.

Competing interests: None.

Patient and public involvement: Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Provenance and peer review: Not commissioned; externally peer reviewed.

Supplemental material: This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Data availability statement

Data are available upon reasonable request. Anonymised data are available from the corresponding author on reasonable request, subject to terms of ethical and regulatory approvals.

Ethics statements

Patient consent for publication

Not applicable.

Ethics approval

The trial was approved by the University of Cape Town Faculty of Health Sciences Human Research Ethics Committee (Ref: 796/2015) and the London School of Hygiene and Tropical Medicine Observational/Interventions Research Ethics Committee (Ref: 7450-2). Participants gave informed consent to participate in the study before taking part.

References

1 Eccles JS . The development of children ages 6 to 14 . Future Child 1999 ;9 :30Not reported44 . 10646256
2 Dewey KG , Begum K . Long-term consequences of Stunting in early life . Matern Child Nutr 2011 ;7 Suppl 3 (Suppl 3 ):5Not reported18 . 10.1111/j.1740-8709.2011.00349.x 21929633 PMC6860846
3 Vaivada T , Akseer N , Akseer S , et al . Stunting in childhood: an overview of global burden, trends, determinants, and drivers of decline . The American Journal of Clinical Nutrition 2020 ;112 (Suppl 2 ):777SNot reported791S . 10.1093/ajcn/nqaa159 32860401 PMC7487433
4 Di Cesare M , Sorić M , Bovet P , et al . The Epidemiological burden of obesity in childhood: a worldwide epidemic requiring urgent action . BMC Med 2019 ;17 . 10.1186/s12916-019-1449-8 PMC6876113 31760948
5 Eckert-Lind C , Busch AS , Petersen JH , et al . Worldwide secular trends in age at pubertal onset assessed by breast development among girls: A systematic review and meta-analysis . JAMA Pediatr 2020 ;174 :e195881. 10.1001/jamapediatrics.2019.5881 32040143 PMC7042934
6 Bikle DD , et al . Vitamin D: production, metabolism and mechanisms of action in . South Dartmouth (MA, 2000 .
7 Gilbert-Diamond D , Baylin A , Mora-Plazas M , et al . Vitamin D deficiency and Anthropometric indicators of Adiposity in school-age children: a prospective study . Am J Clin Nutr 2010 ;92 :1446Not reported51 . 10.3945/ajcn.2010.29746 20926524 PMC3131841
8 Foo LH , Zhang Q , Zhu K , et al . Relationship between vitamin D status, body composition and physical exercise of adolescent girls in Beijing . Osteoporos Int 2009 ;20 :417Not reported25 . 10.1007/s00198-008-0667-2 18629568
9 Zakharova I , Klimov L , Kuryaninova V , et al . Vitamin D insufficiency in overweight and obese children and adolescents . Front Endocrinol (Lausanne) 2019 ;10 . 10.3389/fendo.2019.00103 PMC6406072 30881343
10 Plesner JL , Dahl M , Fonvig CE , et al . Obesity is associated with vitamin D deficiency in Danish children and adolescents . J Pediatr Endocrinol Metab 2018 ;31 :53Not reported61 . 10.1515/jpem-2017-0246 29197860
11 Theodoratou E , Tzoulaki I , Zgaga L , et al . Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials . BMJ 2014 ;348 . 10.1136/bmj.g2035 PMC3972415 24690624
12 Lee HS , Kim YJ , Shim YS , et al . Associations between serum vitamin D levels and precocious puberty in girls . Ann Pediatr Endocrinol Metab 2014 ;19 :91Not reported5 . 10.6065/apem.2014.19.2.91 25077092 PMC4114046
13 Liu S , Zhu X , Wang Y , et al . The association between vitamin D levels and precocious puberty: a meta-analysis . J Pediatr Endocrinol Metab 2020 ;33 :427Not reported9 . 10.1515/jpem-2019-0388 32069239
14 Gou Z , Li F , Qiao F , et al . Causal associations between insulin-like growth factor 1 and vitamin D levels: a two-sample Bidirectional Mendelian randomization study . Front Nutr 2023 ;10 . 10.3389/fnut.2023.1162442 PMC10229803 37266131
15 Nimitphong H , Park E , Lee MJ . Vitamin D regulation of Adipogenesis and Adipose tissue functions . Nutr Res Pract 2020 ;14 :553Not reported67 . 10.4162/nrp.2020.14.6.553 33282119 PMC7683208
16 Ganmaa D , Stuart JJ , Sumberzul N , et al . Vitamin D supplementation and growth in urban Mongol school children: results from two randomized clinical trials . PLoS One 2017 ;12 :e0175237. 10.1371/journal.pone.0175237 28481882 PMC5421751
17 Ganmaa D , Bromage S , Khudyakov P , et al . Influence of vitamin D supplementation on growth, body composition, and pubertal development among school-aged children in an area with a high prevalence of vitamin D deficiency: A randomized clinical trial . JAMA Pediatr 2023 ;177 :32Not reported41 . 10.1001/jamapediatrics.2022.4581 36441522 PMC9706398
18 Middelkoop K , Stewart J , Walker N , et al . Vitamin D supplementation to prevent tuberculosis infection in South African schoolchildren: Multicentre phase 3 double-blind randomised placebo-controlled trial (Vidikids) . Int J Infect Dis 2023 ;134 :63Not reported70 . 10.1016/j.ijid.2023.05.010 37211272
19 Middelkoop K , Micklesfield LK , Walker N , et al . Influence of vitamin D supplementation on bone mineral content, bone turnover markers, and fracture risk in South African schoolchildren: multicenter double-blind randomized placebo-controlled trial (Vidikids) . J Bone Miner Res 2024 . 10.1093/jbmr/zjae007 PMC11240149 38477739
20 Graham BL , Steenbruggen I , Miller MR , et al . Standardization of Spirometry 2019 update. an official American Thoracic society and European respiratory society technical statement . Am J Respir Crit Care Med 2019 ;200 :e70Not reported88 . 10.1164/rccm.201908-1590ST 31613151 PMC6794117
21 Rajakumar K , Moore CG , Yabes J , et al . Estimations of dietary vitamin D requirements in black and white children . Pediatr Res 2016 ;80 :14Not reported20 . 10.1038/pr.2016.46 26959482 PMC4929030
22 Iglay K , Cao X , Mavros P , et al . Systematic literature review and meta-analysis of medication adherence with once-weekly versus once-daily therapy . Clin Ther 2015 ;37 :1813Not reported21 . 10.1016/j.clinthera.2015.05.505 26117406
23 El-Hajj Fuleihan G , Nabulsi M , Tamim H , et al . Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial . J Clin Endocrinol Metab 2006 ;91 :405Not reported12 . 10.1210/jc.2005-1436 16278262
24 Chavarro JE , Watkins DJ , Afeiche MC , et al . Validity of self-assessed sexual maturation against physician assessments and hormone levels . J Pediatr 2017 ;186 :172Not reported8 . 10.1016/j.jpeds.2017.03.050 28438374 PMC5492944
25 Middelkoop K , Walker N , Stewart J , et al . Prevalence and determinants of vitamin D deficiency in 1825 Cape town primary schoolchildren: A cross-sectional study . Nutrients 2022 ;14 . 10.3390/nu14061263 PMC8952729 35334921
26 Ganmaa D , Khudyakov P , Buyanjargal U , et al . Prevalence and determinants of Quantiferon-diagnosed tuberculosis infection in 9810 Mongolian schoolchildren . Clin Infect Dis 2019 ;69 :813Not reported9 . 10.1093/cid/ciy975 30481273 PMC6695506
27 Norris SA , Richter LM . Usefulness and reliability of Tanner pubertal self-rating to urban black adolescents in South Africa . J of Research on Adolesc 2005 ;15 :609Not reported24 . 10.1111/j.1532-7795.2005.00113.x
Publication and source details

Original title: Influence of vitamin D supplementation on growth, body composition, pubertal development and spirometry in South African schoolchildren: a randomised controlled trial (ViDiKids)

Keren Middelkoop; Lisa Micklesfield; Justine Stewart; Neil Walker; David A Jolliffe; Amy E Mendham; Anna K Coussens; James Nuttall; Jonathan Tang; William D Fraser; Waheedullah Momand; Cyrus Cooper; Nicholas C Harvey; Robert J Wilkinson; Linda-Gail Bekker; Adrian R Martineau

BMJ Paediatrics Open · 2024

Correspondence to Prof Adrian R Martineau; a.martineau@qmul.ac.uk

KM and LM are joint first authors.

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.2024https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. UK Medical Research Council MR/M026639/1MR/R023050/1

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T04:48:55.072811+00:00

DOI: 10.1136/bmjpo-2024-002495 · PMC11015302